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Epidemiology provides a means of investigating the underlying architecture of 
complex diseases by combining advances in technology with our current understanding 
of the epidemiology and biology of disease.  In this dissertation, epidemiologic methods 
are applied to further understand the etiology of colorectal cancer, childhood cancers, and 
congenital heart disease (CHD).  
The low-penetrance genes that contribute to risk of familial colorectal cancers 
(CRCs), estimated to account for 35% of all CRCs, are mostly unknown We conducted a 
genome-wide association study (GWAS) of CRC using a population based case-control 
study in northern Israel to survey the genome for low-penetrance susceptibility genes. 
Two leading candidate regions resulting from the Molecular Epidemiology of Colorectal 
Cancer (MECC) study GWAS included rs10210149 on chromosome 2q11.2-q12 and 
rs16931815 on chromosome 12p11.23. After excluding potential pathogenic mutations 
by Sanger sequencing, allele-specific expression analyses were performed for GPR45, 
STK38L, and TGFBRAP1, three genes within the two candidate regions.  GPR45 was 
associated with a 27% increase in expression of one allele for each additional copy of the 
C allele of rs10210149 (p-trend = 0.01).  Further studies are necessary to fully elucidate 
the mechanisms underlying these GWAS associations. 
Common genetic variation and risk of congenital heart disease has not previously 
been studied.  We investigated variation in ISL1, a marker of cells that contribute to 
specific developmental fields of the embryonic human heart, and risk of CHD in a two-
 x
stage case-control study. Eight genic and flanking ISL1 SNPs were significantly 
associated with complex CHD. A replication study analyzed the three SNPs within ISL1 
(rs3762977, IVS1+17C>T, rs1017) in 1,044 new cases and 3,934 independent controls 
and confirmed that genetic variation in ISL1 is associated with risk of CHD. Our results 
demonstrate that two different ISL1 haplotypes contribute to risk of CHD in white 
(Summary Odds Ratio (OR) =1.27, 95% Confidence Interval (CI) 1.09 – 1.48, P = 
0.0018) and black/African American populations (Summary OR=1.57, 95% CI 1.07 – 
2.30, P = 0.0216). 
Linking epidemiologic approaches to cancer epidemiology and cardiovascular 
disease is stimulated by the well known association between selected forms of congenital 
heart disease and cancer. Investigating the relationship between CHD and childhood 
cancer could provide a basis for identifying novel risk factors for both sets of diseases. 
We conducted a retrospective cohort study of CHD at the Children’s Hospital of 
Philadelphia (CHOP), showing that children with CHD demonstrated a 3.7-fold increase 
in the rate of pediatric cancer compared to the US population (Standardized Incidence 
Ratio (SIR) = 3.72, 95% CI = 1.53 – 9.04, p = 0.0037). Rates were higher for children 
with both syndromic (SIR=12.49, 95% CI 1.28 – 121.74, p=0.03) and non-syndromic 
(SIR=2.41, 95% CI 0.88 – 6.60, p=0.086) heart disease. Diagnostic radiation was not 







1.1 Gaining insight into colorectal cancer biology and epidemiology 
 
 Colorectal cancer (CRC) is a significant public health problem in the United 
States, ranking as the third most commonly diagnosed cancer and the fourth leading 
cause of cancer-related deaths (Ferlay et al., 2010). Furthermore, global CRC incidence is 
among the highest of all cancers, ranking as the fourth most commonly diagnosed cancer 
worldwide (WHO, 2003). The epidemiology of CRC has been studied extensively, and 
several confirmed environmental and lifestyle exposures have been identified that either 
increase risk, such as meat intake and smoking (Larsson and Wolk, 2006; Limsui et al., 
2010), or decrease risk, such as physical activity (Wolin et al., 2009) and nonsteroidal 
anti-inflammatory drugs (NSAIDs) (Huls et al., 2003).  Genetic models for colorectal 
carcinogenesis have also been well described, including the chromosomal instability and 
microsatellite instability pathways. Autosomal dominant mutations in key genes in these 
two pathways have been identified in a small number of rare, highly penetrant familial 
syndromes, which account for less than 5% of all CRC (Goss and Groden, 2000; Kemp et 
al., 2004; Marra and Boland, 1995).  Further, family history of non-syndromic CRC is 
associated with a two-fold increase in risk (Carstensen et al., 1996).  These familial 
cancers are estimated to account for an additional 35% of CRC (Tenesa and Dunlop, 
2009), yet the set of low-penetrance genes involved in susceptibility to these colorectal 
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cancers remains an elusive target
 In contrast to the rare, highly penetrant mutations associated with CRC 
syndromes, familial non-syndromic CRC is thought to be attributed to more common, 
moderate- to low-penetrance mutations. A handful of these genes have been identified 
through the implementation of candidate gene studies, including the I1307K mutation in 
APC (Laken et al., 1997) and variants in TGFBR1 (de Jong et al., 2002), which confer 
risks between 1.43 and 2.00.  More recently, advances in genotyping technology have 
allowed investigators to agnostically survey the entire genome in search of additional 
low-penetrance susceptibility genes.  The genome-wide association study (GWAS) 
design has now been widely implemented in colorectal cancer, resulting in the 
identification of several new loci strongly associated with CRC (Broderick et al., 2007; 
Gruber et al., 2007; Houlston et al., 2008; Tenesa and Dunlop, 2009; Zanke et al., 2007).  
The majority of these loci are not located within or near known genes, and the biological 
relevance of some of these signals is unclear.  Others appear to be related to TGFB 
signaling (Tenesa and Dunlop, 2009) and long-range regulation of c-MYC (Sotelo et al., 
2010). 
In the second chapter of this dissertation, I describe a functional study of novel 
associations identified in the Molecular Epidemiology of Colorectal Cancer (MECC) 
GWAS study, a population-based case-control study in northern Israel.  While the MECC 
GWAS has contributed to the replication of chromosomal regions such as 8q24, 18q21, 
and 11q23.1 in multi-center analyses (Tenesa et al., 2008), I focus here on associations 
that have not previously been reported.  The goal of this analysis was to gain insight into 
the biology of colorectal cancer, thus we chose to focus on the biologically relevant 
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hypotheses generated from the MECC GWAS.  I chose to analyze three genes- GPR45, 
TGFBRAP1, and STK38L- within two candidate regions by examining both genetic 
variation and expression patterns.   
While searching for causal variants in genes identified from GWA studies is an 
important step, it is often difficult due to several constraints: 1) appropriate selection of 
subjects for sequencing, 2) adequate coverage of chromosomal regions captured by 
candidate loci, and 3) identification and interpretation of potential causal variants. The 
ultimate goal of these analyses is to understand the functional consequences of GWAS 
signals.  Thus, we chose to follow our sequencing analyses by measuring differences in 
expression between alleles for each of the three genes mentioned above.  Allele-specific 
expression (ASE), discussed in more detail below, has been hypothesized to play an 
important role in susceptibility to complex diseases but has been demonstrated in only a 
few examples. Here, I show that allele-specific expression of GPR45 is associated with 
the risk allele at one of the MECC GWAS loci, rs10210149. GPR45 was associated with 
a 27% increase in expression of one allele for each additional copy of the C allele of 
rs10210149 (p-trend = 0.01). ASE of STK38L and TGFBRAP1 does not seem to play an 
important role in colorectal carcinogenesis, and further studies are necessary to fully 
elucidate the mechanisms underlying these GWAS associations. 
 
1.2 Understanding the genetics of congenital heart disease 
 Congenital heart disease (CHD) is the most common live birth abnormality and 
affects an increasingly large proportion of the population (Hoffman and Kaplan, 2002; 
Hoffman et al., 2004), yet few epidemiologic studies have been conducted to understand 
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the origins of this complex disease. A few maternal exposures have been associated with 
CHD, such as organic solvents and some illnesses, but these account for only 30% of all 
cardiac defects (Jenkins et al., 2007). An additional 13% of CHD is attributed to large-
scale chromosomal abnormalities, such as trisomy or large deletions, although this 
estimate varies widely by specific defect and is expected to increase with improved 
resolution of cytogenetic technologies (Pierpont et al., 2007).  However, even 
considering the combined attributable fractions for all of these known risk factors there 
still remains a large proportion of CHD with no known cause.   
 We are particularly interested in examining the genetic contributions to risk of 
CHD.  Several rare single-gene disorders are associated with CHD.  For example, 
Alagille syndrome is caused by mutations in/deletion of JAG1, Noonan syndrome is 
caused by mutations in PTPN11, SOS1, and KRAS, and Holt-Oram syndrome is caused 
by mutations in TBX5 (Pierpont et al., 2007).  Patients with these disorders present with a 
variety of cardiac defects such as tetralogy of Fallot, septal defects, and pulmonary valve 
stenosis.  Rare mutations in NKX2.5 and GATA4 have also been identified in non-
syndromic patients with atrial septal defects, atrioventricular conduction delay, and 
ventricular septal defects (Garg et al., 2003; Posch et al., 2008; Schott et al., 1998). 
These rare mutations provide evidence that single gene mutations can have a substantial 
phenotypic impact on cardiac development.  Furthermore, studies of offspring of affected 
individuals have shown a significantly higher proportion of children with CHD than 
expected, indicating that genetics may play a larger role in CHD etiology than currently 
appreciated (Rose et al., 1985; Whittemore et al., 1982; Whittemore et al., 1994). 
 To our knowledge, the association between common genetic variation and risk of 
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congenital heart disease has not yet been investigated.  In this dissertation, we employ a 
standard candidate gene approach to investigate this association, specifically focusing on 
the gene ISL1.  Two factors influenced our decision to take this approach.  First, an 
extensive number of developmental experiments have delineated the genetic pathways 
involved in the regulation of cardiac development.  This allowed us to identify ISL1 as a 
promising candidate gene, as discussed in Chapter 3.  Second, at the time the study was 
conducted, no data were available for a sufficiently large number of CHD cases and 
controls to conduct a genome-wide analysis.  Given a compelling biologic rationale, 
genotyping costs, and our unique access to large CHD patient populations, we decided to 
proceed with selective genotyping of the candidate gene ISL1 in a two-stage case-control 
study. 
 While currently described risk factors are typically associated with only subsets of 
CHD, our data suggest that phenotypically heterogeneous congenital heart defects may in 
fact have common origins. In the third chapter of this dissertation, I describe the first 
reported association between common genetic variation in the candidate gene ISL1 and 
risk of CHD. Our results demonstrate that two different ISL1 haplotypes contribute to risk 
of CHD in white (Summary OR =1.27, 95% CI 1.09 – 1.48, P = 0.0018) and 
black/African American populations (Summary OR=1.57, 95% CI 1.07 – 2.30, P = 
0.0216). 
 
1.3 Identifying a link between congenital heart disease and cancer 
 Much remains to be learned about the causes of both congenital heart disease and 
childhood cancers.  As described above, almost 60% of all CHD is unexplained (Jenkins 
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et al., 2007; Pierpont et al., 2007).  Similarly, the causes of the majority of childhood 
cancers are unknown, with both genetics and the environment suggested to be risk factors 
(Stiller, 2004).  Very few firmly established environmental risk factors have been 
identified for these rare cancers, including diagnostic x-rays during pregnancy, Epstein 
Barr virus, hepatitis B, and human immunodeficiency virus (Stiller, 2004). Additionally, 
some genetic syndromes are associated with risk of childhood cancer, including familial 
cancer syndromes, immunodeficiency and bone marrow disorders, and others (Stiller, 
2004).  However, the search for causes of childhood cancers is thought to have been 
substantially hindered by methodological issues such as participation and recall bias.    
 Interestingly, there is substantial evidence for a relationship between 
developmental abnormalities and childhood malignancies. First, several genetic 
disorders, such as Down syndrome and Noonan syndrome, are associated with both 
cardiac defects and an increased risk of pediatric cancers (Denayer et al., 2008; Freeman 
et al., 1998). Second, multiple large cohort studies have identified associations between 
congenital anomalies and childhood cancers (Agha et al., 2005; Bjorge et al., 2008; 
Narod et al., 1997; Rankin et al., 2008). These preliminary observations support the 
hypothesis that there is a causal link between birth defects and childhood cancer, whether 
the common risk factors are environmental or genetic.  However, the specific association 
between congenital heart disease and childhood cancer has never been reported.  
Investigation of this relationship could provide a basis for identifying novel risk factors 
for both sets of diseases.  
 In the fourth chapter of this dissertation, I investigate the epidemiology of 
childhood cancers among children with congenital heart disease. The patient population 
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of the Children’s Hospital of Philadelphia (CHOP) provides a unique opportunity to 
investigate this relationship.  First, the cardiac phenotypes of children undergoing 
operations at the Cardiac Center for CHD are extremely well characterized by highly 
skilled physicians.  Second, many of these children continue to receive long-term care at 
CHOP, indicating that diseases such as cancer are likely to be captured by CHOP 
registries and highlighting the potential for long-term follow-up of these children. Here, I 
describe the first report of an excess of pediatric cancers among children with CHD, 
suggesting that future studies of these children are warranted to elucidate the common 
causes of these diseases. Children with CHD demonstrated a 3.7-fold increase in the rate 
of pediatric cancer compared to the US population (Standardized Incidence Ratio (SIR) = 
3.72, 95% CI = 1.53 – 9.04, p = 0.0037). Rates were higher for children with both 
syndromic (SIR=12.49, 95% CI 1.28 – 121.74, p=0.03) and non-syndromic (SIR=2.41, 
95% CI 0.88 – 6.60, p=0.086) heart disease. 
 
1.4 Conclusions  
 
In this dissertation, I show that epidemiologic methods provide a way to 
understand the underlying architecture of complex diseases.  Consistent with the 
conclusions drawn from other GWAS studies, we suggest that the underlying causal 
variant at rs10210149 affects expression of GPR45 in the MECC study. We also provide 
strong evidence that congenital heart disease is consistent with the common disease – 
common variant hypothesis, and suggest a new role for known regulatory genes of 
cardiomyocytes in human disease.  Finally, we demonstrate a link between the biology 
and epidemiology of both CHD and cancer, suggesting that future studies can take 




Genetic and allele-specific expression analyses of genes identified from a genome 




Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the 
United States, and the fourth most commonly diagnosed cancer worldwide (Ferlay et al., 
2010). While genetic susceptibility to colorectal cancer is well described for a small 
number of rare, highly penetrant familial syndromes, genetic susceptibility to non-
syndromic, familial CRCs is less well understood (Tenesa and Dunlop, 2009). Relatively 
common moderate- to low-penetrance genes are thought to be responsible for a large 
number of these familial colorectal cancers, which has led to a concentrated effort to 
identify these genes.  
 Recently, genome-wide association studies (GWAS) of colorectal cancer have 
been widely implemented in an attempt to comprehensively survey the genome for these 
low-penetrance susceptibility genes. These studies have identified several new loci that 
are strongly associated with CRC risk, including SNPs in genic regions such as SMAD7 
and EIF3H (8q23.3) as well as SNPs in regions far from any known genes, such as 8q24 
(Broderick et al., 2007; Gruber et al., 2007; Houlston et al., 2008; Tomlinson et al., 
2007; Tomlinson et al., 2008; Zanke et al., 2007).  However, the functional significance 
of the majority of these associations is not yet known, other than the reported long-range 
regulation of c-MYC and enhancement of Wnt signaling at 8q24 (Pomerantz et al., 2009; 
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Sotelo et al., 2010; Tuupanen et al., 2009). 
 We conducted a genome-wide association study of colorectal cancer using the 
Molecular Epidemiology of Colorectal Cancer study, a population-based case-control 
study in northern Israel, to identify low-penetrance susceptibility loci.  In this chapter, I 
investigate the genetic and functional basis of associations at two candidate SNPs 
identified from the MECC GWAS.  These two SNPs are rs10210149 on chromosome 
2q11.2-q12 and rs16931835 on chromosome 12p11.23. In a log-additive model, each 
copy of the C allele of rs10210149 was associated with a 12% increase in risk of 
colorectal cancer (OR=1.12, 95% CI 1.07 – 1.18, p = 2.0 x 10-6) (Figure 2.1).  Similarly, 
each copy of the A allele of rs16931815 was associated with an 18% increase in risk of 
colorectal cancer (OR=1.18, 95% CI 1.09 – 1.26, p = 1.2 x 10-4) (Figure 2.2). 
 Located 18.9 kb 3’ of rs10210149 is GPR45, which is a G-protein coupled 
receptor. Little is known about the function of GPR45 itself, but we can surmise potential 
functions of this gene based on what we know about the family to which it belongs. 
GPR45 belongs to a family of proteins that mediate signals to the interior of the cell by 
the activation of heterotrimeric G proteins that in turn activate various effector proteins, 
ultimately resulting in a physiological response (Marchese et al., 1999). The human 
genome encodes thousands of G protein coupled receptors, 150 of which still have 
unknown functions (Vassilatis et al., 2003). GPR109A has been implicated as a tumor 
suppressor gene in colorectal cancer (Thangaraju et al., 2009) and somatic mutations in 
colorectal tumors have been identified in GPR112 and GPR158 (Wood et al., 2007) other 
G-protein coupled receptors, suggesting that this family of proteins may be important in 
carcinogenesis.  
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 The gene TGFBRAP1 is also located in this candidate region, 44.2 kb 3’ of 
rs10210149 and 23.6 kb 3’ of GPR45. TGFBRAP1 encodes for a protein that associates 
with the TGFBR complex and its primary binding partner is TGFBR2 (Wurthner et al., 
2001). Disruption of the TGFB pathway has been extensively reported to result in 
colorectal tumorigenesis, including mutations in TGFB, TGFBR1, and TGFBR2 (Piard et 
al., 2002).  The likelihood that rs10210149 captures mutations in TGFBRAP1 is low 
based on the LD structure of the region, discussed below. However, since mutations in 
TGFBRAP1 could plausibly result in CRC, analysis of this gene is included in this 
chapter.      
 The second candidate region is captured by rs16931815, which is located in intron 
1 of STK38L. This gene encodes a key positive regulatory protein of AMPK-related 
protein kinase 5 (ARK5) in the insulin-like growth factor 1 (IGF-1) pathway, which 
controls cellular processes including cell growth, mitosis, and apoptosis (Suzuki et al., 
2006). IGF-1 receptor binding initiates a signaling cascade that results in the auto-
phosphorylation of STK38L, and ultimately causes the phosphorylation and activation of 
ARK5. ARK5 has been shown to promote tumor invasion and metastasis as well as to 
protect tumor cells from nutrient starvation-induced death (Suzuki et al., 2003; Suzuki et 
al., 2004). Expression of ARK5 has specifically found to be up-regulated in colorectal 
tumors (Kusakai et al., 2004), while STK38L expression has been shown to be up-
regulated in highly metastatic, non-small-cell lung-cancer cell lines (Hergovich et al., 
2006), making STK38L a plausible susceptibility gene for colorectal cancer. 
 In this chapter, I focus on the biologically relevant hypotheses resulting from the 
MECC GWAS.  GPR45, TGFBRAP1, and STK38L are studied to investigate the genetic 
 11
and functional basis of the association between rs10210149, rs16931815 and risk of 
colorectal cancer.   
 
2.2 Study design and methods 
 
2.2.1 Study design 
 This study was separated into two parts: 1) bi-directional Sanger sequencing and 
2) allele-specific expression analysis of genes within candidate loci.  The candidate loci 
resulting from the MECC GWAS were rs10210149 on chromosome 2q11.2-q12, 
rs16931835 on chromosome 12p11.23, and the surrounding regions of DNA in linkage 
disequilibrium with these two SNPs.  We chose to focus this study on only the genes 
within these regions to be able to conduct genetic and functional analyses.  The genes of 
interest in this region are GPR45 (Chr2q11.2-q12), TGFBRAP1 (Chr2q12.1) and STK38L 
(Chr12p11.23).  Sanger sequencing was performed for the exons and exon/intron 
boundaries for each of these genes. This approach does not allow us to detect functional 
variants within introns or in regulatory regions outside of the coding region.  However, 
the goal of sequencing was to search within the coding regions for potentially pathogenic 
variants and to describe the extent of variation for subsequent allele-specific expression 
analyses.  
 Allele-specific expression analysis was performed for GPR45, STK38L, and 
TGFBRAP1 in the second part of this study.  The goal of this analysis was to assess the 
downstream effects of unknown functional mutations captured by rs10210149 and 
rs16931815 in the MECC GWAS.  We hypothesized that the functional mutations 
captured by these SNPs may result in subtle differences in expression between alleles of 
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the genes in these regions, a mechanism previously described in the etiology of a subset 
of CRCs (Castellsague et al., 2010; Yan et al., 2002).  This approach partially 
circumvents the limitations of restricting phase one sequencing to exonic regions, since it 
enables us to detect the effects of cis-acting variants that affect the relative expression of 
alleles for one of these genes.  However, this approach would be unable to detect the 
effects of trans-acting variants at either of these two loci. 
 
2.2.2 Subjects 
 Subjects for this study were selected from the Molecular Epidemiology of 
Colorectal Cancer (MECC) study. The Molecular Epidemiology of Colorectal Cancer 
(MECC) study is a population-based case-control study of incident cases of colorectal 
cancer in the Northern and Haifa districts of Israel (Figure 2.3).  The MECC study is 
designed to take advantage of the relative ethnic homogeneity and corresponding high 
incidence rates of CRC found in Israel. 
 The risk of CRC in Israelis varies widely by ethnicity and country of origin 
(Fireman et al., 2001).  The 5-year age-standardized rate of CRC in Askenazi Jews (born 
in Europe or America) is 41.9/100,000 cancers compared to 25.5/100,000 for Sephardic 
Jews (those born in Asia or Africa).  Jews born in Israel have an intermediate rate of 
32.8/100,000.  Non -Jews in Israel had the lowest CRC rate of 10.1/100,000 cancers.   
Subsequently, Ashkenazi Jews are estimated to have a 3.1-fold higher risk of CRC (95% 
CI 2.2 – 4.3) compared to non-Ashkenazi Jews (Bat et al., 1986). 
 The populations of the Haifa and Northern districts of Israel serve as the source 
population for the MECC study. All individuals in northern Israel were eligible for the 
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study.   MECC subjects were identified through the five main hospitals in northern Israel 
(Carmel, Rambam, BenZion, Nahariya, Afula) and the Kupat Holim Clalit (KHC) 
National Center for Cancer Control database. Cases were identified through rapid case 
ascertainment in the hospitals and through the KHC tumor registry by ICD code for 
cancer of the colon or rectum diagnosed between May 31, 1998 and March 31, 2004. The 
five hospitals used to identify cases in the MECC study provide care for more than 65% 
of individuals diagnosed with CRC in northern Israel, and cases were compared to 
registry incidence data to assure that ascertainment was representative of the general 
population. 
 Controls were identified through a comprehensive database of KHC enrollees and 
were matched to cases by age, sex, clinic, and Jewish ethnicity.  Individuals with a prior 
CRC diagnosis were ineligible for inclusion as controls. Controls in the KHC database 
are assumed to be representative of the general Israeli population, which is reasonable 
since the database covers 60 – 65% of the population. 
 Data collected for the MECC study included biosamples, structured in-person 
interviews, and pathology reviews.  Biosamples collected include blood, frozen tumor 
samples, and formalin-fixed paraffin embedded tumor blocks.  Structured interviews 
were conducted with cases and controls on demographic background, medical history, 
family history, reproductive history, medications, health habits and nutrition (including a 
food frequency questionnaire).  Blood samples were processed to obtain DNA and 
lymphocytes, of which a subset are stored at the University of Michigan. 
 511 Ashkenazi Jewish case-control pairs were selected for Sanger sequencing of 
GPR45.  These subjects were also the same 511 pairs that comprised phase 1 of the 
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MECC GWAS, described above.  Ashkenazi Jewish subjects were selected to increase 
the genetic homogeneity of the sample.  24 Ashkenazi Jewish cases that were 
heterozygous for rs16931815 with a self-reported family history of colorectal cancer 
were selected for sequencing of STK38L. 20 Ashkenazi Jewish cases for whom GPR45 
had been sequenced in this study and were also heterozygous at rs10210149 were 
sequenced for TGFBRAP1. For both STK38L and TGFBRAP1, only cases were selected 
to screen for potential mutations.  Cases and not controls were selected for initial 
sequencing of STK38L and TGFBRAP1 because the primary goal of this analysis was to 
identify potentially pathogenic mutations, not to estimate the association between 
variants and risk of colorectal cancer.  
 MECC subjects were chosen for allele-specific expression analysis using the 
following selection criteria: 1) heterozygous for an exonic SNP within the gene to be 
measured, 2) lymphocytes available at the University of Michigan, 3) Ashkenazi Jewish, 
4) microsatellite stable tumor (cases only), and 5) no known mutations.  Again, Askenazi 
Jewish subjects were chosen to increase the genetic homogeneity of the sample.  We also 
excluded cases with known causes of disease.  Microsatellite instability is a characteristic 
phenotype in tumors with defective DNA mismatch repair; thus cases with microsatellite 
instable tumors were excluded.  Similarly, subjects with known mutations in mismatch 
repair genes or APC were also excluded.  49 cases and 64 controls were selected for 
analysis of ASE at GPR45 among all eligible subjects genotyped for the GWAS SNP 
rs10210149.  27 cases and 22 controls were selected for analysis of ASE at STK38L 
among all eligible subjects genotyped for the GWAS SNP rs16931815.  All cases (n=49) 
and controls (n=46) heterozygous for rs2241801 with available cDNA at the conclusion 
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of the GPR45 and STK38L analyses were selected for analysis of ASE at TGFBRAP1.  
We had 92% power to detect a 10% difference in ASE at GPR45, 59% power to detect a 
10% difference in ASE at STK38L, and 84% power to detect a 10% difference in ASE at 
TGFBRAP1 (Figure 2.4). Power was calculated under the two-sample t-test model for a 
two-sided hypothesis test at α=0.05., which assumes that the asymptotic relative 
efficiency of the two-sample t-test relative to the Wilcoxon rank sum test is close to 1. 
 
2.2.3 MECC genome-wide association study 
 We conducted a GWAS study of CRC in the Molecular Epidemiology of 
Colorectal Cancer (MECC) study. The MECC genome-wide association study was 
implemented in three phases of genotyping and analysis (Figure 2.5).  Phase 1 consisted 
of pooled-genotyping of 511 Ashkenazi Jewish case-control pairs, randomly selected 
from all Ashkenazi Jewish matched pairs in the MECC study.  These subjects were 
divided into 6 case pools and 6 controls pools.  Five cases pools were comprised of 
approximately 94% colon cancers cases and 6% rectal cancer cases, and one pool was 
specifically enriched for rectal cancers (100%).  All subjects were microsatellite stable or 
low.  Subjects were genotyped for more than 350,000 SNPs at Perlegen (Mountain View, 
CA). Phase 1 results were analyzed by estimating the difference in allele frequencies 
between case and control pools for each SNP, utilizing an inflation factor to account for 
the pooled genotyping.  No SNPs were statistically significant at the genome-wide level 
after correction for multiple testing.  However, we proceeded to phase 2 by selecting the 
3,500 SNPs with the largest allele frequency differences. 
 In phase 2, we genotyped 1,500 case-control pairs for 3,500 SNPs at Perlegen 
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(Figure 2.6).  The ethnic distribution of these subjects was representative of the total 
MECC study, including Ashkenazi Jews, Sephardi Jews, and Christian Arabs.  Again, no 
SNPs were statistically significant in standard tests of association using a log-addtive 
model after correction for 3,500 tests.  We prioritized 25 SNPs for phase 3 external 
replication, conducted at the Translational Genomics Research Institute (Phoenix, AZ) 
using Illumina GoldenGate genotyping technology.  SNPs were prioritized based on 
statistical significance in phase 2, statistical significance of closely linked SNPs in GWA 
studies conducted by Tenesa et al. and Zanke et al., and proximity to probable candidate 
genes.  22 of these 25 SNPs were successfully genotyped in 1,866 additional MECC 
subjects, 733 subjects from Spain (Moreno et al., 2006), and 6,812 subjects from 
Germany (Brenner et al., 2006). While the p-values resulting from the MECC GWAS 
analysis were not significant at the genome-wide level, we proceeded by prioritizing 
SNPs with evidence of association in each phase of the MECC GWAS to focus our 
exploration of these signals. 
 
2.2.4 Sanger sequencing and genotyping 
 Sequencing of GPR45, STK38L, and TGFBRAP1 was performed using DNA 
extracted from lymphocytes with the primers given in Table 2.2.  The PCR reaction 
mixtures (20μL) contained 5ng of genomic DNA, 2μl of 10X PCR buffer (Applied 
Biosystems), 1.6μL of 25mM MgCl2 (Applied Biosystems), 0.8μL each of 10mM dNTP 
(New England Biolabs) and 10μM forward and reverse primers, and 1 U of AmpliTaq 
Gold DNA polymerase (Applied Biosystems). Cycling conditions were as follows: Initial 
denaturation at 95°C for 3min, 15 cycles of 95°C for 30sec, 70°C for 45sec (-1° every 
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cycle), 72°C for 1min10sec, 20 cycles of 95°C for 30sec, 55°C for 45sec, 72°C for 
1min10sec, and a final extension at 72°C for 10min. PCR products were sequenced at the 
University of Michigan DNA Sequencing Core, and Mutation Surveyor Software 
(SoftGenetics, LLC., State College, PA, USA) was used to detect variants.  Variants were 
analyzed for potential pathogenicity using Polyphen (http://sift.jcvi.org/) and SIFT 
(http://genetics.bwh.harvard.edu/pph/) for coding variants. Genotypes at rs35946826 in 
GPR45, rs10842902 in STK38L, and rs2241801 in TGFBRAP1 were determined by 
Sanger sequencing of exon 1, the 3’ UTR, and exon 2, respectively.   
  
2.2.5 Allele-specific expression quantification 
 RNA was extracted from frozen lymphocytes of MECC subjects using a trizol- 
chloroform extraction protocol. RNA quality was assessed by gel electrophoresis and UV 
spectrometry.   All RNA samples were treated with 133 units of DNase-I at 65°C for 10 
minutes to eliminate DNA contamination.  cDNA was generated in a 20μL reverse 
transcriptase reaction in the following proportions: 500ng of RNA, 4μL 5X buffer 
(Invitrogen), 2μL each of 2mM dNTP (New England Biolabs), p[dN]6 random primers 
(Roche), and DTT (Invitrogen), 0.5μL RNase out (Invitrogen), and 1uL of M-MLV 
reverse transcriptase (Invitrogen).  Quality of cDNA was assessed by PCR amplification 
of a 238bp product from the GAPDH transcript, with the forward primer 
(GAGTCAACGGATTTGGTCCT) specific to the junction between exons 2 and 3 and 
the reverse primer (TTGATTTTGGAGGGATCTCG) specific to exon 5 of GAPDH. 
cDNA and gDNA were PCR amplified in triplicate using the primers given in 
Table 2.3. ASE was measured at rs35946826 for GPR45, rs10842902 for STK38L, and 
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rs2241801 for TGFBRAP1.  The PCR reaction mixtures (25μL) contained 5ng of 
genomic DNA or 1μL of cDNA, 2.5μl of 10X PCR buffer (Applied Biosystems), 2μL of 
25mM MgCl2 (Applied Biosystems), 1.25μL of 2.5mM dNTP (New England Biolabs), 
0.5μL of each 10μM primer, and 130.75 U of AmpliTaq Gold DNA polymerase (Applied 
Biosystems). Cycling conditions are as follows: Initial denaturation at 95°C for 3min, 50 
cycles of 95°C for 345sec, 60°C for 45sec, 72°C for 45sec, and a final extension at 72°C 
for 10min.  5μL of PCR product was used for Pyrosequencing according to the standard 
Streptavadin- Sepharose bead-capture protocol provided by Qiagen.  Results were 
included in analysis only if assigned a quality score of “check” or “pass” by the 
PyroMarkMD software using default settings. 
 
2.2.6 Statistical methods 
 
 Descriptive characteristics were assessed using frequency tables and the means 
procedure in SAS (version 9.2).  Statistically significant differences in clinical and 
epidemiologic characteristics between cases and controls were determined using chi-
square tests for categorical variables and analysis of variance (ANOVA) for continuous 
variables.  
 Allele-specific expression was calculated as  
 
ASE =

























where n indicates the number of pyrosequencing replicates performed for cDNA and m 
indicates the number of pyrosequencing replicates performed for genomic DNA (gDNA).  
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Allele-specific expression was analyzed as a continuous variable using the Wilcoxon 
rank-sum statistic by case-control status and the Kruskal-Wallis Test by GWAS SNP 
genotype.  Trend in allele-specific expression by GWAS SNP genotype was measured 
using linear regression.  
 
2.3 Results  
2.3.1 Identification of candidate regions 
 The goal of this study was to gain insight into the functional consequences of 
genetic variants associated with risk of colorectal cancer in the MECC GWAS. Of the 22 
SNPs genotyped in phase 3, none reached statistical significance in an analysis including 
samples from phases 2 and 3 after Bonferroni correction for 3,500 tests (Table 2.1). We 
proceeded by prioritizing SNPs based on those with evidence for association in each 
phase of the MECC GWAS. The top two most significant SNPs were rs10210149 on 
chromosome 2 and rs16931815 on chromosome 12.  In a log-additive model, each copy 
of the C allele of rs10210149 was associated with a 12% increase in risk of colorectal 
cancer (OR=1.12, 95% CI 1.07 – 1.18, p = 2.0 x 10-6).  Similarly, each copy of the A 
allele of rs16931815 was associated with an 18% increase in risk of colorectal cancer 
(OR=1.18, 95% CI 1.09 – 1.26, p = 1.2 x 10-4). Rs10210149 on chromosome 2q11.2-q12, 
rs16931835 on chromosome 12p11.23, and the surrounding regions of DNA in linkage 
disequilibrium with these two SNPs are considered the candidate loci from the MECC 
GWAS in this chapter. 
 
2.3.2 Sequencing of genes within candidate regions   
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 We first examined the coding regions of three genes (GPR45, TGFBRAP1, 
STK38L) within these candidate loci in an attempt to identify the functional variants 
captured by rs10210149 and rs16931815.  GPR45, a 1.725 kb gene comprised of a single 
exon, is located on chromosome 2q11.2-q12.  In HapMap samples of European ancestry 
(http://hapmap.ncbi.nlm.nih.gov/), variants flanking GPR45 are in strong linkage 
disequilibrium with the GWAS SNP rs10210149.  No polymorphisms within GPR45 
were genotyped in HapMap samples of European ancestry.  Rs10210149 lies 18.9 kb 5’ 
of GPR45 and is in high linkage disequilibrium with SNPs spanning a 25.8 kb region that 
includes GPR45 (Figure 2.7).  Among 29 SNPs within this region, the average D’ with 
rs10210149 is 0.931 and the average R2 is 0.232.  This indicates that mutations within 
this region are likely to be captured by variation in rs10210149. 
 We first fully sequenced GPR45 as well as 447 bp 5’ and 209 bp 3’ of the gene to 
search for mutations in the 511 Ashkenazi Jewish case-control pairs from Phase 1 of the 
MECC GWAS.   We identified 10 variants within and around GPR45 using Sanger 
sequencing (Table 2.4).  Eight of the ten variants identified were relatively rare with 
minor allele frequencies (MAF) no greater than 2%, and five of the ten variants had been 
previously reported in dbSNP (www.ncbi.nlm.nih.gov/projects/SNP/).  Only three 
variants were within the coding region, and of these three only rs35946826 coded for a 
non-synonymous amino acid change (L312F).  This change from leucine to 
phenylalanine was not predicted to be damaging to the GPR45 protein by either SIFT or 
PolyPhen. 
 To better understand the role of L132F as a candidate mutation, we estimated the 
association between this SNP and risk of colorectal cancer in the sequenced subjects.  
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Rs35946826 was associated with a 1.34-fold increase in risk (95% CI 1.05 – 1.71, 
p=0.02), which is consistent in magnitude and direction with the GWAS SNP 
rs10210149.  We next conducted a haplotype analysis using the expectation-
maximization algorithm to describe the relationship between these two SNPs.  A single 
haplotype was associated with risk of CRC, which was perfectly captured by the C allele 
of rs102101049.  The C-C (rs10210149-rs35946826) haplotype was associated with a 
1.45-fold increase in risk of CRC (95% CI 1.12 – 1.87, p=0.004) compared to the T-T 
haplotype.  This analysis indicates that the C allele of the GWAS SNP rs10210149 better 
captures risk of colorectal cancer than does the C allele of rs39546826.  
 We next looked at TGFBRAP1, which is located 23.6 kb 3’ of GPR45 and 44.2 kb 
3’ of the GWAS SNP rs10210149 (Figure 2.7).  TGFBRAP1 is comprised of 12 exons on 
the reverse strand of chromosome 2q12.1.  In HapMap samples of European ancestry, 
variation within TGFBRAP1 is not strongly associated with rs10210149.  Among 92 
SNPs in this 62.6 kb gene, the average D’ with rs10210149 is 0.340 and the average R2 is 
0.017.  Thus, variants within TGFBRAP1 are less likely to be captured by rs10210149 
compared to variants within GPR45, and GPR45 remains the most likely susceptibility 
gene in this region of chromosome 2.  
 We next sequenced the 11 exons and exon/intron boundaries of TGFBRAP1 in 20 
Ashkenazi Jewish MECC cases for whom GPR45 had been sequenced to both search for 
functional variants and to characterize the variation in this gene.  A total of 15 variants 
were identified among these 20 cases (Table 2.4), of which 12 had been previously 
reported in dbSNP or the Ensembl database (http://ensembl.org/).  Six variants were in 
the coding region of the gene, and only one of these coded for a non-synonymous amino 
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acid change.  This previously unreported variant in exon 11, EX11-43C>T, coded for a 
change from histidine to argine and was present in a single subject.  Both the SIFT and 
PolyPhen programs predicted this amino acid change to be benign.  Due to the limited 
number of cases sequenced for TGFBRAP1, it is likely that we would not have been able 
to identify any functional variants in this gene.  However, we decided to proceed with 
functional analysis of TGFBRAP1 rather than continue an exhaustive search for a 
functional mutation in this low-priority gene.  
 The third gene of interest identified from the MECC GWAS, STK38L, is located 
on chromosome 12p11.23.  The GWAS SNP rs16931815 is located within intron 1 of this 
gene and is subsequently in high linkage disequilibrium with STK38L variation (Figure 
2.8).  STK38L consists of 14 exons and spans 81.4 kb.  Fifty-one SNPs were genotyped in 
HapMap samples of European ancestry, and among these the average D’ with 
rs16931815 is 0.83 and the average R2 is 0.088.  Rs16931815 is also in linkage 
disequilibrium with the gene ARNTL2, located 7.5 kb 3’ of STK38L.  However, we chose 
to focus our analyses on STK38L since rs16931815 lies within the gene. 
 We next sequenced all 14 exons and exon/intron boundaries of STK38L in 24 
Ashkenazi Jewish MECC cases with a family history of colorectal cancer.  Only 5 
variants were identified, and four of these SNPs had been previously reported in dbSNP 
(Table 2.4).  Although all 5 variants were relatively common with MAFs between 0.125 
and 0.210, none were located in the coding region of the gene.  Again, it is likely that we 
were unable to identify a mutation in this gene due to the limited number of cases 
sequenced.  However, we decided to also proceed with functional analysis of STK38L 
rather than continue a comprehensive search for a functional variant in this gene. 
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2.3.3 Allele-specific expression analyses of GPR45, TGFBRAP1, & STK38L  
 Since we were unable to detect any mutations in GPR45, TGFBRAP1, or STK38L, 
we decided to pursue functional analysis of these genes.  This approach allows us to 
ascertain whether GPR45, TGFBRAP1, or STK38L are targets of the functional variants 
captured in the MECC GWAS without identifying the functional variants themselves.  
Thus, functional analysis in this study offers a method of identifying genes and their 
corresponding regulatory regions for future high-coverage sequencing to identify causal 
mutations.  While it is possible that the genes affected by functional variants in these two 
loci lie outside of the candidate regions on chromosomes 2 and 12, we chose to first 
proceed with analyses of GPR45, TGFBRAP1, and STK38L. 
  Given the modest magnitudes of association observed at both rs10210149 and 
rs16931815, we hypothesized that the effects of the mutations captured by these SNPs 
may also be modest.  More specifically, we proposed that the underlying functional 
variants could cause subtle changes in gene expression that result in the attenuation of 
expression of one allele.  This process, known as allele-specific expression (ASE), is 
widespread in the normal human genome (Lo et al., 2003) and has been proposed as a 
mechanism involved in susceptibility to complex diseases (Knight, 2005).  Several 
examples have been reported, including DAPK1 and chronic lymphocytic leukemia 
(Lynch et al., 2002) and APC and familial adenomatous polyposis (Yan et al., 2002).  In 
this chapter, we conducted allele-specific expression analyses for GPR45, TGFBRAP1, 
and STK38L in MECC subjects.   
 The primary goal of these allele-specific expression analyses was to identify 
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changes in expression associated with variation at the GWAS SNPs.  To implement this 
method, we took advantage of the characterization of genetic variation by Sanger 
sequencing to identify exonic variants.  To be informative for ASE, subjects had to be 
heterozygous at the exonic SNP measured.  A total of 113 Ashkenazi Jewish MECC 
participants with no known mutations and microsatellite stable tumors (cases only) were 
informative for ASE analysis of rs35946826 in exon 1 of GPR45 (Table 2.5).  As 
described above, rs35946826 codes for a leucine to phenylalanine change at amino acid 
312 of the GPR45 protein.  Rs35946826 is in linkage disequilibrium with the GWAS 
SNP rs10210149 with a D’ of 0.958 and an R2 of 0.47; specifically, the C allele of 
rs35946826 is in LD with the C (risk) allele of rs10210149.   
 Among these 113 informative subjects, 49 were colorectal cancer cases (43.4%) 
and 64 were controls (56.6%).  The mean age of these subjects was 74.2 years (standard 
deviation (SD) = 10.1 years) and did not significantly differ by GWAS SNP genotype 
(p=0.12). Allele-specific expression may be influenced by both genetic environmental 
factors.  While the subjects analyzed for ASE were not randomly selected from the 
MECC study and the sample sizes are small, we were interested in identifying any 
obvious environmental confounders of the relationship between GWAS SNP genotype 
and ASE values. The variable examined here were smoking, vegetable intake, and 
aspirin/NSAID use. Sex, smoking (ever and pack-years), vegetable intake, and daily 
aspirin/NSAID use were not significantly different by GWAS SNP genotype.   
 Allele-specific expression was measured in cDNA generated from lymphocyte 
mRNA for GPR45 at rs35946826 using pyrosequencing technology.  The relative 
expression of the C allele compared to the T allele in cDNA was normalized to the 
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relative expression of these alleles in genomic DNA to account for any assay-specific 
differences in allelic amplification.  Among all 113 subjects, the mean increase in 
expression of the C allele compared to the T allele was 32% (ASE = 1.32, SD = 0.68).  
The minimum value of ASE corresponded to a 0.36-fold decrease in expression of the C 
allele and the maximum value of ASE corresponded to a 4.62-fold increase in the 
expression of the C allele.  When analyzed by rs10210149 genotype, a significant 
difference in median ASE values was observed (Kruskal-Wallis p = 0.03). For each 
additional copy of the C allele of rs10210149, there was a 27% increase in the expression 
of the C allele of rs35946826 (p trend = 0.01) (Figure 2.9a).  No difference was observed 
in ASE by case-control status (Wilcoxon p=0.28) (Figure 2.9b).  The relationship 
between GPR45 ASE, case-control status, and rs10210149 genotype were consistent 
when analyzed on a log scale.  No difference in median ASE values was observed 
between cases and controls (Wilcoxon p = 0.28). Rs10210149 was highly significantly 
associated with log-ASE (Kruskal-Wallis p = 0.016; p trend = 0.0049). 
 We next measured allele-specific expression for TGFBRAP1 at rs2241801 to 
investigate whether rs10210149 affected expression at both GPR45 and TGFBRAP1. A 
total of 95 Ashkenazi Jewish MECC participants that met selection criteria were 
informative for ASE analysis of rs2241801 in exon 2 of TGFBRAP1 (Table 2.6). 
rs2241801 displays low LD with the GWAS SNP rs10210149 with a D’ of 0.098 and an 
R2 of 0.005.  Among these 95 subjects, 49 were colorectal cancer cases (51.6%) and 46 
were controls (48.4%).  The mean age of these subjects was 72.1 years (SD = 9.8 years) 
and did not significantly differ by GWAS SNP genotype (p=0.31). Subjects heterozygous 
for the risk allele were 5.16 times more likely to be ever smokers (95% CI 1.28 – 20.77, 
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p=0.02) and subjects homozygous for the risk allele were 3.11 more likely to be ever 
smokers (95% CI 0.73 – 13.20, p=0.12) compared to subjects homozygous for the non-
risk allele of rs10210149. Sex, vegetable intake, and daily aspirin/NSAID use were not 
significantly different by GWAS SNP genotype.  
 Allele-specific expression was measured for TGFBRAP1 at rs2241801 using the 
method described above, quantified as the relative expression of the A allele compared to 
the G allele.  Among all 95 subjects, the mean increase in expression of the A allele 
compared to the G allele was 7% (ASE = 1.07, SD = 0.29).  The minimum value of ASE 
corresponded to a 0.03-fold decrease in expression of the A allele and the maximum 
value of ASE corresponded to a 2.2-fold increase in the expression of the A allele.  No 
significant difference in ASE values was observed by either rs10210149 genotype  
(Kruskal-Wallis p = 0.98) or case-control status (Wilcoxon p=0.29) (Figure 2.10). ASE 
values were also not significantly different by smoking history (Wilcoxon p=0.32).  Thus, 
we conclude that rs10210149 variation is associated with differences in expression of 
GPR45 but not TGFBRAP1, which is consistent with the LD structure in this region of 
chromosome 2. The relationship between TGFBRAP1 ASE, case-control status, and 
rs10210149 genotype were consistent when analyzed on a log scale.  No difference in 
median ASE values was observed between cases and controls (Wilcoxon p = 0.29) or by 
rs10210149 genotype (Kruskal-Wallis p = 0.98). 
We then evaluated allele-specific expression of genes within candidate loci 
identified from the MECC GWAS by examining STK38L.  A total of 49 Ashkenazi 
Jewish MECC participants that met selection criteria were informative for ASE analysis 
of rs10842902 in the 3’ UTR of STK38L (Table 2.7).  rs10842902 displays very high LD 
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with the GWAS SNP rs16931815 with a D’ of 1 and an R2 of 0.14.  Among these 49 
informative subjects, 27 were colorectal cancer cases (55.1%) and 22 were controls 
(44.9%).  The mean age of these subjects was 73.0 years (SD = 8.0 years) and did not 
significantly differ by GWAS SNP genotype (p=0.31). Sex, vegetable intake, smoking 
(history and pack-years) and daily aspirin/NSAID use were also not significantly 
different by GWAS SNP genotype.  
 Allele-specific expression was quantified for STK38L at rs10842902 as the 
relative expression of the A allele compared to the G allele.  Among all 49 subjects, the 
mean increase in expression of the A allele compared to the G allele was 10% (ASE = 
1.10, SD = 0.60).  The minimum value of ASE corresponded to a 0.01-fold decrease in 
expression of the A allele and the maximum value of ASE corresponded to a 4.0-fold 
increase in the expression of the A allele.  No significant difference in ASE values was 
observed by either rs16931815 genotype  (Kruskal-Wallis p = 0.41) or case-control status 
(Wilcoxon p=0.44) (Figure 2.11). The relationship between STK38L ASE, case-control 
status, and rs10210149 genotype were consistent when analyzed on a log scale.  No 
difference in median ASE values was observed between cases and controls (Wilcoxon p 
= 0.44) or by rs10210149 genotype (Kruskal-Wallis p = 0.41). Thus, we conclude that 
rs16931815 variation is not strongly associated with differences in expression of STK38L 
alleles and does not explain the GWAS signal in this sample of the MECC population.  
Further analyses are required to understand the functional consequences associated with 




Genome-wide association studies of colorectal cancer in England, Scotland, 
Canada, and international replication populations have identified ten new low-penetrance 
susceptibility loci (Tenesa and Dunlop, 2009), but the causal variants at any these loci 
have yet to be uncovered despite extensive fine mapping and resequencing. This suggests 
that the underlying causal variants affect gene expression.  Five of these ten GWAS 
variants capture genes in the TGFB signaling pathway, such as SMAD7 (Broderick et al., 
2007; Tenesa et al., 2008), BMP2 (Jaeger et al., 2008), and BMP4 (Houlston et al., 
2008), suggesting a key role for this pathway in colorectal cancer susceptibility.  
Additionally, one of these GWAS variants on 8q24, rs6983267, has been shown to affect 
the regulation of c-MYC via a long-range enhancer (Sotelo et al., 2010).  Elucidating the 
functional consequences of these GWAS variants has been challenging, but provides an 
opportunity for understanding the mechanisms of colorectal cancer. 
The results presented in this chapter are consistent with the conclusions drawn 
from the GWAS studies and subsequent functional analyses described above.  We have 
identified a significant trend in allele-specific expression of GPR45 that is associated 
with rs1021019. To better understand the significance of ASE at GPR45, there are 
several methods we could employ.  First, we could examine the colorectal tumors of the 
MECC patients with extreme ASE values for loss of heterozygosity (LOH) to identify 
whether there is loss of the normally expressed allele.  This would argue for a direct 
functional relationship between over-expression of GPR45 and risk of colorectal cancer.  
We could additionally perform high-coverage sequencing at this locus to better define the 
ASE-associated haplotype and to potentially fine-map the disease-causing variant.  To 
better understand risk of CRC associated with rs16931815, we could perform sequencing 
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in a larger number of subjects for both STK38L and ARNTL2, including the intronic and 
5’ regions for these genes.   
While ASE analysis was successful in identifying subtle changes in GPR45 
associated with a GWAS SNP, it is unlikely that this method will be widely employed for 
large-scale GWAS candidate gene screening.  This is due not only to the time and 
resource-intensive nature of this analysis, but also to the fact that many of the variants 
identified in GWA studies are in “gene-deserts”.  These variants are likely to be located 
in regulatory regions or non-coding RNA gene, but identifying genes to analyze as 
potential targets of these regulatory SNPs would be extremely challenging.  Nevertheless, 
we will continue to investigate the genetic and functional basis of these associations. 
 One limitation of this study is that Sanger sequencing was performed for 
TGFBRAP1 and STK38L in a small number of subjects and was restricted to the coding 
regions of these genes.  The sample size for this analysis was too small to confidently 
conclude that no functional variants exist in the coding regions of these two genes.  
Additionally, we would have missed any variants that were located in the promoter 
region or other proximal regulatory regions, as well as functional variants located within 
introns. 
A second limitation of this study is that we only used one SNP per gene to 
measure ASE.  It is possible that SNP location influences gene expression patterns. 
However, our choice to measure only one SNP per gene was in large part determined by 
the patterns of variation within these genes.  Specifically, there were very few exonic 
SNPs with minor allele frequencies in GPR45 and STK38L greater than 5%.   Selecting 
SNPs for analysis with small minor allele frequencies would have led to small sample 
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sizes, limited by the number of informative subjects that also met the other selection 
criteria.  
 Finally, we had little power to detect very small changes in ASE in this study.  
For example, we had only 40% power to detect a 5% difference in allele-specific 
expression of GPR45 and 13% power to detect a 2.5% difference in allele-specific 
expression for this gene.  Similarly, we had only 30% power to detect a 5% difference in 
allele-specific expression of TGFBRAP1 and 10% power to detect a 2.5% difference in 
allele-specific expression for this gene.  We had the lowest power for the STK38L 
analyses, where we had only 20% power to detect a 5% difference in allele-specific 
expression of GPR45 and 6.7% power to detect a 2.5% difference in allele-specific 
expression for this gene.  Clearly, very subtle changes in the relative expression of alleles 
would not be detected in this study, which could still potentially have a causal effect on 
colorectal carcinogenesis.  
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Table 2.1 22 SNPs genotyped in Phase III of the MECC GWAS 
   Phase 2 Phase 2 + 3 combined 
SNP Gene Description OR (95%CI) p OR (95%CI) p 
rs544670  1MB 5’ of PI3K 1.04 (0.95 - 1.14) 0.47 1.07 (1.00 – 1.16) 6.0x10-2 
rs10210149  5’ of GPR45 and TGFBRAP1 1.07 (1.01 - 1.14) 7.1x10-3 1.12 (1.07 - 1.18) 2.0x10-6 
rs2193075 PARD3B PARD3B par-3 partitioning defective 3 homolog B 1.04 (0.98 - 1.11) 0.15 1.03 (0.98 – 1.09) 7.5x10-2 
rs2016993  near zinc finger proteins 1.02 (0.95 - 1.08) 0.61 1.05 (1.00 – 1.11) 1.0x10-3 
rs313587  gene dessert 1.04 (0.99 - 1.10) 0.14 1.09 (1.04 – 1.14) 8.4x10-4 
rs7733404 MCC mutated in colorectal cancers 1.07 (1.00 - 1.13) 4.0x10-2 1.06 (1.00 – 1.13) 8.2x10-4 
rs17012429 CNTN3 contactin 3 (plasmacytoma associated) 1.10 (1.00 - 1.21) 5.7x10-2 1.14 (1.04 – 1.25) 5.2x10-3 
rs2576794  5’ of GPR45 and TGFBRAP1 1.06 (1.01 - 1.13) 2.8x10-2 1.08 (1.03 – 1.14) 8.8x10-4 
rs4631835 C10orf81 chromosome 10 open reading frame 81 1.05 (0.98 - 1.11) 0.15 1.06 (1.01 – 1.13) 2.7x10-2 
rs2068452 CDH12 cadherin 12, type 2 (N-cadherin 2) 1.06 (0.89 - 1.26) 0.54 1.06 (0.92 – 1.23) 3.4x10-1 
rs6034187 C20orf133 chromosome 20 open reading frame 133 1.01 (0.95 - 1.07) 0.76 1.04 (0.99 – 1.10) 7.7x10-2 
rs3773966 IL1RAP interleukin 1 receptor accessory protein 1.06 (0.96 - 1.17) 0.27 1.01 (0.92 – 1.10) 8.0x10-1 
rs255153  5’ of INMT 1.03 (0.97 - 1.10) 0.30 1.06 (1.01 – 1.12) 1.6x10-2 
rs17383284 PSD3 pleckstrin and Sec7 domain containing 3 1.00 (0.94 - 1.07) 0.92 1.03 (0.97 – 1.09) 4.2x10-1 
rs11647078  gene dessert 1.09 (1.02 - 1.16) 7.6x10-3 1.02 (0.97 – 1.07) 4.8x10-1 
rs9385571 AKAP7 A kinase (PRKA) anchor protein 7 1.04 (0.98 - 1.10) 0.21 1.06 (1.01 – 1.11) 2.9x10-2 
rs6980478  3’ of CYP7B1 1.06 (0.98 - 1.15) 0.13 1.09 (1.02 – 1.16) 7.2x10-3 
rs17159640 IFRD1 interferon-related developmental regulator 1 1.04 (0.91 - 1.18) 0.57 1.04 (0.95 – 1.15) 3.4x10-1 
rs16931815 STK38L serine/threonine kinase 38 like 1.19 (1.10 - 1.29) 1.0x10-4 1.18 (1.09 - 1.26) 1.2x10-4 
rs8049247 CDH3 cadherin 3, type 1, P-cadherin (placental) 1.08 (1.00 - 1.16) 5.1x10-2 1.02 (0.96 – 1.09) 5.8x10-1 
rs10816788 EPB41L4B erythrocyte membrane protein band 4.1 like 4B 1.06 (0.98 - 1.15) 0.16 1.00 (0.94 – 1.07) 9.7x10-1 
rs2689264 FTO fatso 1.04 (0.95 - 1.13) 0.39 1.05 (0.99 – 1.12) 9.8x10-2 
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Table 2.2 Sequencing primers for GPR45, STK38L, and TGFBRAP1 
Gene Exon  Forward primer Reverse primer Product size 
GPR45 1 CCTTTCTCTTGTGGAGCAGG ACAGCATGATGTCGGAGAAG 814 
 1 GCAACACTGTGGTCTGCATC ACTTTGGGGAGGATTTGGAA 897 
 1 CCCATCGTCTACTGCTGGA CGGATGTGCTTCTCACTTCA 859 
STK38L 1 ACAGGTTTGGCGTAAAAACG CTGGACACCCAAAGACACCT 488 
 2 TAACTCCTGGTTTTGCCACC AATTGGCATGTCATACGGGT 592 
 3 TTTAGGCAGGAGCGTGAAGT ATGAAAAGTCACTGGGGGTG 352 
 4 TGTGAAAGAGCAACCTTGGA ATATATTTGCAGCAGTAGTGACTTTT 556 
 5 GAGCTTTTGGAGAGGTGTGC ACTGCGTCAGTGGATGCTC 800 
 6 AGAGGCCTCAGCTTCACGTA CAGTGAACCCAGAACGGTAA 599 
 7,8,9 TCCACCTTTGAGGCATTTTC GAACCAAGGCATAAAATTCTCTT 940 
 10,11 GGTTTGACGAGTTGCTCCTT CTTCCCCCACAAAAGTGAAA 795 
 12 TGATAATTTCTCTGTTTCCATGTTG ACCTTTCCCATTCAAAGCCT 154 
 13,14 AGGATGAGAAAGCCTTGGGT TGGTGATGCAGCTACCTGAG 885 
 3'UTR ACATGACCATGAAGGCTGCT TCACATTGAGAAATCCCCAG 957 
TGFBRAP1 1 CCCTCCTCCTGTGTAGGTGA CCTGAGTGTGACCCGAATTT 996 
 2 GCAGCCTCTGTTTCTGCTTC TCATCAAGCACTGGTCAAGC 926 
 3 CCATGCTTATTTGGAAGCCT TGCATCCTTAAAGGTTTGGC 555 
 4 CAGTTTGGGGAAAGCAGTGT GCAGTGCCTTCTCAGTCACA 442 
 5 GACGTGCATTTGGGAAAGAT ACCGTATCCACCTGAAGCAC 417 
 6 ACATGATTACCCTGTCCCCA GAGCCTCAGTAAGGGTGCAG 537 
 7 GCTGATGGGGAGAGGTTGTA AATGTACCCAGCTCATTGGC 488 
 8 CCTGGCTGATGGTTGTAGGT CAGACTTCTGAGGGGTCGAG 864 
 9,10 GGTTTGGGAAGCACAGTCAC CCACCCGCTTGATATGAGTT 934 
 11 AGGGAGCCAGGTTGACTTTT CTCTGCCTCTGCTCACACAG 722 




Table 2.3 Pyrosequencing primers for GPR45, STK38L, and TGFBRAP1 
Gene SNP Primer Sequence 
GPR45 rs35946826 Forward Biotin-TACAGCCTCCTGTCTGTGTTTAGC 
  Reverse GATGGGGTTGAAGACGGACT 
  Sequencing CGGACTTGAGGTAACTGA 
TGFBRAP1 rs2241801 Forward Biotin-ACAGCTGCAGAGACACTTGG 
  Reverse ATGGTTCTGCGTTTGACAGAG 
  Sequencing TGAGTGCTGAGGCCG 
STK38L rs10842902 Forward Biotin-TTTCCTGTGGGCATGCTGT 
  Reverse TTGCCCTTTAATAAGCTGACCTC 




Table 2.4 Variants identified in GPR45, STK38L, and TGFBRAP1 by Sanger 
sequencing 
GENE VARIANT LOCATION EFFECT MAF 
GPR45 rs17636399 5’   0.223 
 5’-160C>G 5’   0.014 
 rs17030715 5’   0.014 
 5’-31G>A 5’   0.002 
 rs2576727 Exon 1 T27T 0.005 
 rs56355385 Exon 1 T168T 0.014 
 rs35946826 Exon 1 L312F 0.167 
 EX1-227G>A 3’ UTR  0.006 
 EX1-185G>A 3’ UTR  0.019 
 3’+65T>G 3’   0.006 
     
STK38L rs1615928 Intron 1  0.132 
 rs10771336 Intron 10  0.125 
 rs2242185 Intron 10  0.167 
 IVS10-41C>T Intron 10  0.125 
 rs4369500 Intron 12  0.210 
     
TGFBRAP1 rs2241801 Exon2 R82R 0.158 
 ENSSNP5509498 Intron 2  0.155 
 rs6709616 Intron 2  0.100 
 rs12476720 Exon 3 R240R 0.211 
 IVS4-32InsT Intron 4  0.050 
 rs2679833 Intron 5  0.158 
 rs2241799 Exon 6 N432N 0.370 
 IVS7+191C>T Intron 7  0.025 
 rs2304543 Intron 9  0.211 
 rs2250659 Intron 9  0.083 
 rs2250658 Intron 9  0.083 
 rs11676273 Exon 10 L643L 0.550 
 rs2241798 Intron 10  0.211 
 rs2241797 Exon 11 H724R 0.100 




Table 2.5 Epidemiologic characteristics of subjects in GPR45 ASE analysis (n=113) 
  rs10210429  
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  7 (53.8) 
  6 (46.2) 
 
0.62* 
Pack years Mean=40.8 SD=29.6 Mean=27.4 SD=16.5 Mean=46.3 SD=34.4 Mean=39.0 SD=17.3 0.27† 
Veg tert 3 
Veg tert 2 
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  4 (30.8) 
 
0.23* 
* Calculated by Fisher’s exact test 




Table 2.6 Epidemiologic characteristics of subjects in TGFBRAP1 ASE analysis (n=49) 
  rs10210149  
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18 (60.0) 0.05* 
Pack years Mean=38.5 SD=35.2 NA Mean=35.1 SD=30.7 Mean=56.9 SD=43.4 0.19† 
Veg tert 3 
Veg tert 2 
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17 (60.7) 0.99* 
* Calculated by Fisher’s exact test 





Table 2.7 Epidemiologic characteristics of subjects in STK38L ASE analysis (n=95) 
  rs16931815  
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  8 (44.4) 
10 (55.6) 0.52* 
Pack years Mean=31.5 SD=22.5 NA Mean=27.2 SD=18.9 Mean=35.8 SD=26.2 0.46† 
Veg tert 3 
Veg tert 2 
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  5 (27.8) 
13 (72.2) 0.49* 
* Calculated by Fisher’s exact test 









Figure 2.1 GWAS associations at chromosome 2 The –log10 p-values around the 
signal at rs10210149 are shown by study.  The orange dot indicates the p-value for 
rs10210149 in the combined Phase 2 and 3 analyses (MECC and replication studies).  
The white dots indicate p-values from Phase 1 MECC GWAS genotyping,  the green dots 
indicate p-values from Phase 2 MECC GWAS genotyping, the blue dots indicate p-
values from a Canadian GWAS (Zanke, et al. 2007), and the red dots indicate p-values 
from the Greman and Spanish replication samples in Phase 3 of the MECC GWAS. 
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Figure 2.2 GWAS associations at chromosome 12 The –log10 p-values around the 
signal at rs16931815 are shown by study.  The orange dot indicates the p-value for 
rs16931815 in the combined Phase 2 and 3 analyses (MECC and replication studies).  
The white dots indicate p-values from Phase 1 MECC GWAS genotyping,  the green dots 
indicate p-values from Phase 2 MECC GWAS genotyping, the blue dots indicate p-
values from a Canadian GWAS (Zanke, et al. 2007), and the red dots indicate p-values 
from the Greman and Spanish replication samples in Phase 3 of the MECC GWAS. 
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Figure 2.3 Molecular Epidemiology of Colorectal Cancer study design The design of 
the MECC study, a population-based case-control study of colorectal cancer in the 




Figure 2.4 Power to detect differences in allele-specific expression means The power 
for detecting various differences in the mean ASE values for GPR45 (n=113), 
TGFBRAP1 (n=49), and STK38L (n=95) are shown. 
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Figure 2.5 MECC genome-wide association study design The design of the MECC 
GWAS is shown below, conducted in three phases.  Phase I was comprised of a whole 
genome scan and pooled analysis of 511 Ashkenazi Jewish MECC case-control pairs 
followed by individual-level genotyping to confirm results of the top 5,000 SNPs.  Phase 
II was comprise of individual-level genotyping of 3,500 SNPs for 1,500 MECC case-
control pairs.  Phase III was comprised of replication of 22 SNPs in an independent set of 
cases and controls from MECC, Spain, and Germany. 
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Figure 2.6 Manhattan plots of Phase II and III MECC GWAS Top panel displays the 
–log10 p-values for 3,500 SNPs genotyped in Phase II of the MECC GWAS by 
chromosome and position.  The bottom panel shows results of the combined phase 2 and 
Phase 3 analysis of the 22 SNPs selected for phase 3 genotyping are shown.  –Log10 p-











Figure 2.7 Linkage disequilibrium patterns on chromosome 2 at rs10210149 A 
linkage disequilibrium (LD) heatmap measured by D’ is shown for SNPs along 122.3 kb 
of chromosome 2, measured using data from HapMap for CEPH subjects.  Red indicates 
high LD while yellow indicates low LD.  The GWAS SNP rs10210149 is indicated at its 






Figure 2.8 Linkage disequilibrium patterns on chromosome 12 at rs16931815 A 
linkage disequilibrium (LD) heatmap measured by D’ is shown for SNPs along 216.9 kb 
of chromosome 12, measured using data from HapMap for CEPH subjects.  Red indicates 
high LD while yellow indicates low LD.  The GWAS SNP rs16931815 is indicated at its 




Figure 2.9 Allele-specific expression of GPR45 Distribution of ASE measured at 
rs35946826 in exon 1 of GPR45 by a) rs10210149 genotype and b) case-control status.  




Figure 2.10 Allele-specific expression of TGFBRAP1 Distribution of ASE measured at 
rs2241801 in exon 2 of TGFBRAP1 by a) rs10210149 genotype and b) case-control 




Figure 2.11 Allele-specific expression of STK38L Distribution of ASE measured at 
rs10842902 in the 3’ UTR of STK8L by a) rs16931815 genotype and b) case-control 










 Congenital heart disease (CHD) is the most common live birth defect in the 
United States, affecting 1 in 20 live births (Hoffman and Kaplan, 2002; Hoffman et al., 
2004).  1 out of 100 CHD cases requires an intervention, reflecting the wide range in 
severity and morphology of these types of defects.  The causes of many cases of 
congenital heart disease remain unknown.  Those risk factors that have been identified, 
such as maternal exposures or chromosomal abnormalities, are typically associated with 
specific subsets of CHD (Jenkins et al., 2007; Pierpont et al., 2007).  Perhaps 
contributing to this lack of identifiable CHD risk factors, congenital heart defects are 
often investigated as etiologically and morphologically separate diseases.  However, 
examination of the gene pathways that control early human cardiac development may 
reveal significant insight into the common origins of a broad subset of congenital heart 
disease. 
 Currently, 13% of CHD is attributed to chromosomal abnormalities detectable by 
chromosome analysis (Pierpont et al., 2007), although this estimate varies widely by type 
of defect.  Improvements in the resolution of these technologies are revealing that the 
proportion of CHDs with chromosomal abnormalities may be even higher than this 
original estimate.  Furthermore, studies of the offspring of affected individuals have 
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shown a significantly higher proportion of children with CHD than expected, suggesting 
an important role for genetic susceptibility to CHD (Rose et al., 1985; Whittemore et al., 
1982; Whittemore et al., 1994).  However, no common genetic variants have been 
robustly associated with the risk of complex CHD, and only a few rare mutations have 
been identified in non-syndromic CHD patients.  These include mutations in NKX2.5 and 
GATA4, which have been identified in individuals with atrial septal defects, 
atrioventricular conduction delay, and ventricular septal defects (Garg et al., 2003; Posch 
et al., 2008; Schott et al., 1998). 
 The functions of NKX2.5 and GATA4 are well described and are centrally 
involved in the regulation of a subset of cardiomyocytes known as the primary heart 
field.  During vertebrate cardiac development, the 3-dimensional structure of the heart is 
formed from the differentiation and interaction of multiple tissue derivatives, or fields 
(Gruber and Epstein, 2004). The primary and secondary heart fields of the embryonic 
disc give rise to the intracardiac structures of the heart under the influence of adjacent 
tissues (Buckingham et al., 2005). The first lineage contributes to the formation of both 
ventricles, the atrioventricular canal, and both atria.  NKX2.5 and GATA4 are key 
myocardial regulatory genes in this process, and the primary heart field is marked by 
expression of either TBX5 or the first wave of NKX2.5 (Wu et al., 2008).  The secondary 
heart field provides an especially important source of cells, contributing to the outflow 
tract and essentially all heart regions other than the left ventricle (Buckingham et al., 
2005).   This second population of cells is marked by expression of the ISL1 gene 
(Laugwitz et al., 2005; Moretti et al., 2006; Wu et al., 2008). 
 Considering that rare NKX2.5, GATA4, and TBX5 mutations have been reported in 
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CHD patients, it is plausible that other genes that are critical to cardiomyocyte regulation 
and differentiation are also involved in CHD etiology.  Specifically, ISL1 is a likely 
candidate susceptibility gene for human CHD.  Consistent with the integral role of ISL1 
in the regulation of the secondary heart field, Isl1-/- mouse embryos display distinct 
cardiac abnormalities: dysmorphic hearts with abnormal looping, ventricular misidentity, 
hypoplastic outflow tracts, and hypoplastic atrial structures (Ahlgren et al., 1997; Cai et 
al., 2003).  Although mice deficient in Isl1 harbor defects in cardiac morphogenesis, the 
role of ISL1 in human congenital heart disease is unknown.  We hypothesized that 
genetic defects in ISL1 disrupt early human cardiac development, resulting in congenital 
defects in secondary heart field-derived structures.  We conducted a two-stage case-
control study of CHD to test this hypothesis, and in this dissertation we describe the first 
association between common genetic variation and risk of non-syndromic, complex 
CHD. 
 
3.2 Subjects and methods 
 
3.2.1 Study design 
 This study of the candidate gene ISL1 was performed in three parts.  First, I 
performed Sanger sequencing of ISL1 in 99 children with CHD from the Children’s 
Hospital of Philadelphia (CHOP).  All 6 exons and exon/intron boundaries were 
sequenced to search for pathogenic mutations and to characterize the variation in this 
gene.   
 The second part of this study consisted of a case-control study at the Children’s 
Hospital of Philadelphia, denoted as the stage 1 study. In this study, we estimated the 
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association between common genetic variation in ISL1 and the risk of congenital heart 
disease.  Cases and controls were derived exclusively from CHOP and are referred to in 
this dissertation as United States (US) subjects.  Analyses were conducted separately for 
whites and blacks/African Americans to understand the patterns of risk in these separate 
groups and as one strategy to adjust for genetic differences between these two groups.  
Common genetic variation was examined in all subjects at 3 SNPs within ISL1, identified 
from Sanger sequencing.  Data were available for 27 SNPs surrounding ISL1 for only a 
subset of subjects. 
 In the third part of this study, we sought to replicate the results from the initial US 
case-control study.  To accomplish this, we conducted a second case-control study 
denoted as the stage 2 study.  This analysis was again conducted separately for whites 
and blacks/African Americans.  Stage 2 white subjects were comprised of additional 
cases and controls from CHOP, cases and controls from CONCOR in the Netherlands, 
and CHD cases ascertained at SickKids Hospital in Toronto, Canada.  All stage 2 white 
subjects were newly identified and distinct from stage 1 whites.  Common genetic 
variation was examined at the 3 SNPs within ISL1 for all subjects.  Data were available 
for the 27 ISL1-flanking SNPs for US white subjects only.  Stage 2 black/African 
American subjects were ascertained exclusively at CHOP, the only children’s hospital in 
our consortium with a large percentage of black/African American patients. These 
black/African American patients were also completely distinct from stage 1 subjects.  
Only the 3 SNPs within ISL1 were examined for these subjects.  Analyses were 
conducted separately for stage 2 subjects, followed by a combined analysis of the stage 1 




 United States cases and controls were recruited from the Children’s Hospital of 
Philadelphia (CHOP) between 12/12/2003 and 08/25/2008 on a protocol approved by the 
Institutional Review Boards of CHOP and the University of Michigan, and parents 
provided written informed consent.  The proportion of all eligible cases seen at the CHOP 
Cardiac Center in this time period that participated in this study was 31.6% (613/1939).  
US cases were children with complex congenital heart disease requiring surgical repair.  
Guided by lineage-tracing analyses in rodents, cases were defined by diseases 
representative of secondary heart field defect phenotypes (Black, 2007; Cai et al., 2003; 
Sun et al., 2007).  These include defects of atrial septation, ventricular septation, conus 
positioning, and great vessel alignment (Figure 3.1).  US controls were patients without 
congenital heart disease recruited through the CHOP Health Care Network by CHOP 
clinicians and nursing staff. The controls were screened by nurse practitioners who 
evaluated medical records for surgical repair of a cardiac defect. All cases and controls 
were evaluated by a physician.  
 Ethnicity for US cases was determined by self-report in stage 1.  Self-reported 
ethnicity was not available for stage 2 cases, so ethnicity was determined by principal 
components analysis (PCA) in stage 2.  Ethnicity for US controls was determined by 
PCA in both stages, also because self-reported ethnicity was not available.  PCA was 
performed at the Center for Applied Genomics at CHOP for stage 1 controls.  A different 
method was used to determine ethnicity for stage 2 controls.  First, the first two principal 
components were plotted for stage 1 cases of known ethnicity, which demonstrated that 
the first principal component distinguished between white and black/African American 
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cases (Figure 3.2).  This distinction was made using a cutoff of PC1≤0.025 to define 
ethnicity as white and PC1>0.025 to define ethnicity as black/African American.  
Similarly, the first principal component sufficiently distinguished between stage 1 white 
and blacks/African American controls, using a cutoff of PC1≤0.0059 to define ethnicity 
as white and PC1>0.0059 to define ethnicity as black/African American.  The 
implications of the probable misclassification bias resulting from this classification 
method are discussed below.  
 Stage 2 cases and controls from the US, Toronto, and the Netherlands were 
recruited on institution-specific protocols, and were also approved by the IRBs of CHOP 
and the University of Michigan.  Stage 2 US cases and controls were ascertained as 
described for stage 1.  Dutch and Canadian cases were also children with complex 
congenital heart disease requiring surgical repair.  The distribution of cardiac defects 
among these cases differed slightly from US cases, though were selected using the same 
second heart field defect criteria (Figure 3.1).  Dutch controls were patients without 
congenital heart disease recruited through UMC Utrecht.  All stage 2 subjects were 
evaluated by a medical doctor, and ethnicity was determined by self-report.  
 
3.2.3 Genotyping  
 The 6 exons and exon/intron boundaries of ISL1 were sequenced in the first 99 
cases using bidirectional Sanger sequencing, accomplished at the University of Michigan 
sequencing core.  The primers and cycling conditions are given in Table 3.1.  Variants 
were identified using Mutation Surveyor software (State College, PA).  GeneSplicer 
(Pertea et al., 2001) and NetGene2 (Brunak et al., 1991; Hebsgaard et al., 1996) were 
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used to bioinformatically predict splice site variants. 
 Stage 1 and stage 2 genotypes were requested for 27 ISL1-flanking SNPs from the 
Center for Applied Genomics at CHOP that had been performed using the Illumina 
HumanHap 550 SNP array. Genotypes for only these 27 SNPs were obtained from the 
Center for Applied Genomics.  At the time of the study, no additional genotypes on this 
platform were obtained or analyzed. Data was available for these 27 SNPs for white US 
cases and controls in both stage 1 and stage 2. 
 Genotypes for the 3 SNPs within ISL1 (rs3762977, IVS1+17C>T, rs1017) were 
determined using one of two methods: 1) bidirectional sequencing of ISL1 exons 1 and 6 
or 2) genotype imputation. Stage 1 genotyping of these 3 SNPs was performed using 
bidirectional Sanger sequencing as described above. Stage 2 Canadian and Dutch cases 
were also genotyped using bidirectional sequencing. Imputation was performed for the 3 
SNPs within ISL1 for stage 2 US cases and all controls using 97 SNPs surrounding these 
3 SNPs. Haplotypes were reconstructed for all 100 SNPs in 484 controls using 
FastPHASE14. These phased, reconstructed haplotypes were then used as the reference 
haplotypes for genotype imputation using the MACH program (Li Y, 2006; Scheet and 
Stephens, 2006). Each genotype at each SNP was associated with a QC score, interpreted 
as the posterior probability that the imputed genotype represents the true genotype. 
 Genotyping accuracy by sequencing was assessed with repeat sequencing of a 
subset of genotypes. Two measures were used to assess imputation error for the three 
ISL1 SNPs. The first measure, εj, captures genotyping error, discrepancies with the 
reference panel, and recurrent mutation (Li Y, 2006; Scheet and Stephens, 2006).  
Slightly lower data quality is observed for larger estimates of εj. Values of εj were small 
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for each of the three SNPs: rs3762977 εj = 0.0229, IVS1+17C>T εj = 0.0007, rs1017 εj = 
0.0434. The second measure of imputation error was the agreement between genotypes 
determined by sequencing and genotypes determined by imputation for a subset of stage 
1 cases and controls for whom both genotypes were available. Agreement was measured 
using the Kappa statistic in SAS (version 9.1) at various QC cutoffs. No QC values for 
any of the 3 imputed SNPs were less than 0.5. Inclusion of all imputed genotypes 
(regardless of QC value) resulted in Kappa statistics of at least 0.889 for each of the 3 
SNPs, confirming that the genotype imputation method is robust. Agreement was also 
measured among subjects carrying at least one minor allele for each of the three SNPs. 
For rs3762977 the Kappa statistic was 0.614 and for rs1017 the Kappa statistic was 
0.918.  For IVS1+17C>T, 75% of all cases were called heterozygotes by both Sanger 
sequencing and imputation. The implications of genotype misclassification are discussed 
below.  All genotype frequencies were assessed for departure from Hardy-Weinberg 
equilibrium in controls. 
 
3.2.4 Statistical methods 
  Single SNP analyses were conducted using unconditional logistic regression to 
calculate odds ratios as implemented in SAS (version 9.1). Haplotypes were estimated 
and tested for association with CHD using the haplo.stats package in R (http://cran.r-
project.org). Significance testing was adjusted for multiple comparisons with Bonferroni 
correction, and 95% confidence intervals were calculated from the parameters estimated 




3.3 Results  
3.3.1 Characterization of ISL1 variation 
 We hypothesized that genetic mutations or variants in the gene ISL1 disrupt early 
cardiac development, resulting in a wide variety of congenital defects in the heart 
structures derived from the secondary heart field.  To address this hypothesis, we first 
sequenced ISL1 in 99 cases of complex congenital heart disease.  This was done in an 
attempt to identify either mutations or functional variants within the gene and to 
characterize the overall variability at this locus. 15 polymorphisms were identified (Table 
3.2).  Most variants were rare (8/15) and 6 had been previously reported in dbSNP.  
Variation was observed only in exons 1, 4, and 6 and in introns 1 and 5 in the initial 99 
cases; thus, further genotyping was restricted to these regions. All exonic polymorphisms 
were either synonymous mutations or occurred in noncoding regions that were not 
predicted to be splice-site abnormalities.  We concluded that none of these variants were 
of clear functional significance; therefore, we proceeded by examining the association 
between common variation in ISL1 and risk of CHD in a case-control study.  
 
3.3.2 Stage 1: US case-control study in white subjects 
 We conducted a two-stage candidate gene study to test the hypothesis that 
germline common genetic variants in ISL1 confer susceptibility to non-syndromic human 
CHD. The stage 1 case-control study was comprised of 300 CHD cases (white n=160, 
black/African American n=70, other/unknown=70) and 2,201 CHD-free controls (white 
n=2091, black/African American n=110). Cases were children diagnosed with complex, 
non-syndromic CHD, all of which required operative repair. Guided by lineage-tracing 
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analyses in rodents, cases were defined by diseases representative of secondary heart 
field defect phenotypes (Black, 2007; Cai et al., 2003; Sun et al., 2007).  Defects of the 
second heart field are potentially pathogenic in anatomic defects of both the right and left 
sides of the normal heart due the contribution of secondary heart field derivatives in both 
inflow and outflow tracts. These include defects of atrial septation, ventricular septation, 
conus positioning, and great vessel alignment. 
 We analyzed 30 SNPs spanning a 237 kb region around ISL1 on chromosome 
5q11.1, selected to capture variation in this region based upon linkage disequilibrium 
patterns in subjects of European ancestry (http://www.hapmap.org). No genome-wide 
data were available for this hypothesis-driven, candidate gene study. Eight individual 
SNPs (rs6867206, rs4865656, rs6869844, rs2115322, rs6449600, IVS1+17C>T, rs1017, 
rs6449612) were significantly associated with risk of CHD at the α=0.05 level (Figure 
3.3) located within a single LD block. Indeed, HapMap data demonstrate D’ =1 between 
three of these SNPs (rs6869844, rs6449600, rs6449612) and each of the four Hapmap 
published SNPs within ISL1 (rs3792733, rs2288468, rs3811911, rs991216). The 
moderate magnitudes of association seen at these SNPs (OR = 1.32 – 2.30) were 
consistent with those expected under the common disease – common variant hypothesis 
(Reich and Lander, 2001; Wang et al., 2005). Furthermore, the closest gene to ISL1 is 
located in a different LD block more than 540 kb upstream (PARP8), reducing the 
likelihood that these SNPs are capturing an association between a gene other than ISL1 
and risk of CHD. Of the six ISL1-flanking SNPs, rs6869844 remained statistically 
significant after adjustment for multiple testing (P = 0.039 with Bonferroni correction for 
30 SNPs). Located 15.7 kb 5’ of ISL1, rs6869844 was associated with a 50% increase in 
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risk for each additional T allele in a log-additive model (Odds ratio (OR) = 1.51, 95% 
confidence interval (CI) = 1.18-1.95). 
 Three SNPs analyzed in stage 1 (rs3762977, IVS1+17C>T, rs1017) were located 
within the ISL1 gene in the 5’UTR, intron 1, and the 3’ UTR, respectively (Figure 3.4). 
To diminish the potential for population stratification in this sample, we first restricted 
our stage 1 analyses to white cases with non-syndromic CHD and white controls (n=100 
cases, 576 controls) with genotype data available for these SNPs. IVS1+17C>T was 
associated with a more than two-fold increase in risk among whites with the C/T 
genotype (OR = 2.30, 95% CI 1.12 – 4.70, P = 0.023) (Table 3.3a). Rs1017 was highly 
significant in a log additive model, with an 81% increase in risk associated with each 
additional copy of the T allele (OR = 1.81, 95% CI 1.29 – 2.54, P = 0.0007). Dominant 
and recessive models for rs1017 were also highly significant. Children with the A/T or 
T/T genotype had a 2.28-fold increase in risk compared to children with the A/A 
genotype (OR = 2.28, 95% CI 1.35 – 3.87, P = 0.002). Similarly, children with the T/T 
genotype had a 2.21-fold increase in risk compared to children with the A/A or A/T 
genotype (OR = 2.11, 95% CI 1.17 – 3.80, P = 0.013). 
 We then delineated the patterns of risk in these subjects by using the expectation 
maximization (EM) method to estimate haplotypes and risk of CHD from the 6 ISL1-
flanking SNPs (rs6867206, rs4865656, rs6869844, rs2115322, rs6449600, rs6449612) 
and the 3 SNPs within ISL1 (rs3762977, IVS1+17C>T, rs1017). The three SNPs within 
ISL1 most effectively captured risk of CHD. In stage 1 whites, an additive model fit the 
data well (global haplotype association P = 0.0008). Two haplotypes, A-C-T and A-T-T 
(rs3762977- IVS1+17C>T -rs1017), were strongly associated with CHD risk (Table 
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3.3b). A child’s risk of CHD was 2.01 times greater with each copy of the A-C-T 
haplotype compared to the A-C-A haplotype (95%CI 1.35 – 2.99, P = 0.0006) and 3.30 
times greater with each copy of the A-T-T haplotype (95% CI 1.52 – 7.18, P = 0.0026). 
 
3.3.3 Stage 2: US, Canadian, and Dutch case-control study in white subjects 
 To understand the role of ISL1 variation and risk of CHD in other populations, we 
studied ISL1 variation in a second, independent analysis of samples from the US, Canada, 
and the Netherlands.  Stage 2 cases and controls were completely distinct from those in 
initial stage 1. The stage 2 white subjects consisted of 995 cases (US n=265, Canada 
n=94, Netherlands n=636) and 2089 controls (North America n=1446, Netherlands 
n=643).  For the purpose of this analysis, cases from the US and Canada were combined 
and compared to US controls, indicated as North American cases and controls.  The allele 
frequencies at each of the three ISL1 SNPs were comparable between US and Canadian 
cases (Table 3.4).  This indicates that estimates resulting from the North American 
analysis are not confounded by differences in allele frequencies between the US and 
Canadian cases.  
 Data were available for the 27 ISL1-flanking SNPs for only US whites in stage 2.    
Single SNP analyses in the stage 2 US white population confirmed the association at 10 
of these SNPs within and around ISL1 (Figure 3.5).  Further investigating this 
relationship in stage 2, we next examined the 3 SNPs within ISL1 in all North American 
whites.  Rs1017 was significantly associated with risk of CHD in a log-additive model, 
where each copy of the T allele at rs1017 increased a child’s risk of CHD by 22% (OR = 
1.22, 95% CI 1.05 – 1.44, P = 0.022) (Table 3.5a).  Also consistent with the stage 1 
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analysis, the A-C-T haplotype was significantly associated with risk among North 
American whites (Table 3.5b). Each copy of the A-C-T haplotype conferred a 33% 
increase in risk (OR = 1.33, 95% CI 1.08 – 1.62, P = 0.0065) compared to the A-C-A 
haplotype.  
 We next estimated the association between the three ISL1 SNPs and risk of CHD 
using Dutch cases and controls from stage 2.  In single SNP analyses, none of the three 
SNPs were associated with risk of congenital heart disease (Table 3.6a).  Similarly, there 
was no significant association between ISL1 variation and CHD risk in a haplotype 
analysis.  However, a haplotype analysis that combined all stage 2 whites demonstrated 
that the A-C-T haplotype is significantly associated with risk among whites (Global P = 
0.00003) (Table 3.7).  Each copy of the A-C-T haplotype conferred an 18% increase in 
risk (OR = 1.18, 95% CI 1.00 – 1.39, P = 0.0485) compared to the A-C-A haplotype.  We 
next performed a combined analysis of both stage 1 and stage 2 for the A-C-T haplotype 
in whites, which was highly significant (Table 3.8, Figure 3.6).  Each copy of the A-C-T 
haplotype was associated with a 27% increase in risk of CHD (95% CI 1.09 – 1.48, P = 
0.0018). 
 The precise distribution of CHD diagnoses was different between stage 1 and 
stage 2 populations (Figure 3.1). However, hypoplastic left heart syndrome (HLHS) and 
D-transposition of the great arteries (D-TGA) were the most common diagnoses in both 
stages, with HLHS accounting for 19.4.0% in Stage 1 and 7.0% in Stage 2 and D-TGA 
accounting for 14.0% in Stage 1 and 28.4% in Stage 2. To ensure that the stage 2 
replication of our original findings was not influenced by the differences among case 
populations, we performed a subset analysis to include only the most frequent diagnoses 
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in both stages, HLHS and D-TGA. Associations with rs1017 and the A-C-T haplotype in 
stage 1, stage 2, and combined analyses were consistent with analyses utilizing cases of 
all secondary heart field defects in both magnitude and significance of association (Table 
3.9). This indicates that risk of CHD is consistently associated with common genetic 
variation in ISL1 in whites whether considering all secondary heart field defects 
combined or subsets of the two most common diagnoses. 
 
3.3.4 Stage 1: US case-control study in black/African American subjects 
 To understand the role of ISL1 variation in an ethnically distinct sample, we 
investigated these 3 SNPs in the stage 1 black/African American cases and controls using 
the exact same phenotypic definitions for cases with non-syndromic CHD (n=54 cases, 
110 controls). Compared to whites, analysis at these three loci demonstrated a different 
pattern of association between ISL1 and risk of CHD (Table 3.10a). While no association 
was observed at rs3762977 in whites, black/African American children were at a more 
than 2-fold increase in risk for each additional copy of the G allele at this locus (OR = 
2.21, 95%CI 1.15-4.24; P=0.017). Variation at IVS1+17C>T was extremely rare 
among blacks/African Americans with only 1 heterozygous control and 0 heterozygous 
cases, and no association between rs1017 and risk of CHD was observed (OR = 1.08, 
95%CI 0.66-1.76; P=0.756). However, as with the single SNP analyses, haplotype 
analysis showed that the black/African American sample demonstrated a distinct pattern 
of risk at the ISL1 locus (Figure 3.6, Table 3.10b).  The A-C-T haplotype was not 
associated with increased risk of CHD among blacks, and the A-T-T haplotype was not 
identified in any cases or controls of black/African American ancestry. In contrast, the G-
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C-T haplotype was associated with a 2-fold increase in risk of CHD (OR = 1.99, 95%CI 
1.02-3.87; P=0.043). 
 
3.3.5 Stage 2: US case-control study in black/African American subjects 
 To determine whether our findings in stage 1 blacks/African Americans would be 
consistent in a new set of samples, we analyzed a distinct set of 49 US black/African 
American cases and 1,845 US black/African American controls (Table 3.11a). In this 
stage 2 sample, the relative risk for rs3762977 was consistent with that seen in stage 1 
blacks/African Americans (OR = 1.20, 95% CI 0.74 – 1.95, P = 0.457), although not 
statistically significant. Similarly, the G-C-T haplotype did not reach statistical 
significance among blacks/African Americans in stage 2 (Table 3.11b), but the relative 
risk for this haplotype was consistent with that seen in stage 1 (OR = 1.28, 95% CI 0.75 – 
2.19, P = 0.359).  The G-C-T haplotype was significantly associated with risk of CHD in 
a summary analysis of stage 1 and stage 2 blacks/African Americans, where each copy of 
this haplotype conferred a 57% increase in risk (95% CI 1.07 – 2.30, P = 0.0216) (Table 
3.12, Figure 3.6).  These data provide evidence that genetic variation in ISL1 is 
associated with risk of CHD in blacks/African Americans, and this risk is characterized 
by a pattern of variation distinct from that in whites. 
 
3.4 Discussion 
 Our results demonstrate that two different ISL1 haplotypes contribute to risk of 
CHD in white and black/African American samples. These data provide strong evidence 
that congenital heart disease is consistent with the common disease – common variant 
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hypothesis in two ethnically distinct samples. Further work is necessary to determine 
whether these two haplotypes capture ancestrally distinct causative mutations or are in 
linkage disequilibrium with a single disease-causing mutation. Our observations of 
different risk haplotypes in whites and black/African Americans is intriguing and 
suggests that different risk alleles are present in the ISL1 locus within these groups. This 
provides an opportunity for identifying causal variants through subsequent studies with 
admixture mapping or deep sequencing within these two patient samples. 
One limitation of this study is that there is likely to be misclassification of 
ethnicity among the stage 2 US subjects for whom ethnicity was determined by principal 
components analysis.  In stage 2, we expect misclassification to be non-differential since 
ethnicity was determined using SNPs that should be independent of case-control status, 
although we are unable to directly measure this. This type of measurement error due to 
population stratification could be important if the degree of misclassification was very 
large and differed among cases and controls.  However, we do not anticipate this to 
meaningfully affect our results since misclassification of ethnicity is expected to be 
independent of case-control status and ISL1 genotype status. Further, if misclassification 
of ethnicity is in fact non-differential, then we would expect this type of measurement 
error to bias our results towards the null. 
  To determine whether using principal components analysis to classify ethnicity 
produces different results compared to another method of classifying ethnicity, we 
employed the ANCESTRYMAP (Patterson et al., 2004) program as an alternative 
method.  This program uses genotype information from two ancestral populations to 
estimate admixture in a test population. We used 26 of 136 ancestral informative markers 
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(AIMs) on chromosome 5 for which genotype information for stage 2 subjects was 
available (Smith et al., 2004). None of these 26 SNPs were in linkage disequilibrium with 
the ISL1 locus based upon LD patterns in subjects of European ancestry 
(http://www.hapmap.org). The 26 AIM genotypes for the two ancestral populations, the 
Centre d'Etude du Polymorphisme Humain (European) and Yoruban (African) HapMap 
samples, were downloaded from http://www.hapmap.org. We ran the ANCESTRYMAP 
program using default parameters to obtain estimates of the percent European ancestry 
for all US stage 2 subjects of unknown ancestry as well as a subset of US stage 1 subjects 
of known ancestry (Figure 3.7). A bimodal distribution of the percent European ancestry 
was observed among all subjects, which was highly correlated with self-reported 
ethnicity among stage 1 subjects. Subjects with greater than 65% European ancestry were 
defined as white, and subjects with less then 65% European ancestry were defined as 
black/African American. Single SNP and haplotype analyses were performed using 
ANCESTRYMAP-defined ethnicity, and results were qualitatively similar to those 
described above. This suggests that using PCA to define ethnicity does not produce 
results that are substantially different from another method of classifying ethnicity. 
Another limitation of this study is that there is likely to be genotype 
misclassification in stage 2 US subject and Dutch controls due to imputation error.   First 
considering stage 2 US subjects, we would expect genotype misclassification to be non-
differential with respect to case-control status since SNPs used for imputation were not 
linked to ISL1 variation. We would not anticipate this to substantially bias the effect 
estimates for the three ISL1 SNPs, although this would depend on the degree of 
misclassification for each SNP.  Estimates of genotyping error, εj, were small for each of 
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the three SNPs: rs3762977 εj = 0.0229, IVS1+17C>T εj = 0.0007, rs1017 εj = 0.0434.  It 
is possible that stage 2 US analyses of rs1017 and rs3762977 were influenced by 
genotyping error; however, the degree of misclassification is estimated to be minor and 
should not significantly affect the estimates of association in analyses of stage 2 US 
subjects. 
Genotype misclassification among stage 2 Dutch samples would be differential 
with respect to case-control status, since cases were genotyped using Sanger sequencing 
while genotypes for controls were imputed.  As mentioned above, estimates of 
genotyping error were small. Whether this would bias estimates of association for the 
three ISL1 SNPs towards or away from the null depends on whether controls were more 
or less likely to be classified as having the risk allele for rs1017.  This could partially 
explain the differences in the direction and magnitude of effect estimates for rs1017 
between the stage 2 North American and Dutch analyses. 
 Finally, we had limited power to detect an association between rs3762977 and 
risk of CHD in stage 2 blacks/African Americans for a two-sided hypothesis test at 
α=0.05.  In this population of 49 cases and 1,845 controls, if we assume that the minor 
allele frequency for rs3762977 is equal to 18.4%, then the minimum detectable odds ratio 
with 80% power is 2.42.  Furthermore, we only have 25% power to detect an odds ratio 
of 1.5 and 60% power to detect an odds ratio of 2.0.  In other words, if the true 
association between ISL1 variation and risk of CHD in blacks/African Americans is 
modest (i.e. OR < 2), then we had insufficient power to detect this association in stage 2.  
This is consistent with the analysis of stage 2 blacks/African Americans, and further 
argues that a combined analysis of stage 1 and stage 2 subjects is appropriate. 
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 The biologic rationale is compelling: ISL1 is a transcription factor that marks 
cardiac progenitor cells and controls secondary heart field differentiation, and new 
evidence suggests that purified populations of ISL1+ progenitor cells are capable of self-
renewal and expansion into cardiomyocytes, smooth muscle, and endothelial lineages (Bu 
et al., 2009). In addition to providing new insight into the variety of congenital heart 
disease phenotypes that can be produced from second heart field defects in humans, our 
observations also may provide the basis for a more integrated understanding of the 
molecular basis of human congenital heart disease.
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Table 3.1 PCR primers & conditions for ISL1 sequencing 
 
Exon Primer Sequence Ta°* 
1  F: 5' GAG CAG CGC CAC AGG AGG C 3' 62  R: 5' CTT GGC ACC TCA GCC TGT GC 3' 
2  F: 5' GTA GGA AGT AAA CGG TTA GTC 3' 56  R: 5' CTT GTA TGA CTA CAC TGA GGC 3' 
3  F: 5' AGT GCC GGC CTG AAG TGA C 3' 62 
 R: 5' ACA GGC TGG CTT AAC CTG G 3' 
4  F: 5' AAG CGA GCC TCC AGC CCA G 3' 62  R: 5' GTG CGA TCC TGC GTA CCA G 3' 
5  F: 5' AAC ATG TTG GGA TTG GTT GGG 3' 56 
 R: 5' TTC CAT CTG GGA GCT GAC AC 3' 
6 
 F: 5' ATG AAT ACT ATT CCA GTG TCC 3' 56 
 R: 5' GTT TGG CAA GGC AAT GAC C 3' 
 F: 5' TCT AGT CCA TCC TAA TCT G 3' 
56  R: 5’ AAA GTG GCA AGT CTT CCG AC 3’ 
 
* Cycling conditions for all primer sets: Initial denaturation at 95°C for 10min, 30 cycles 






Table 3.2 ISL1 variation identified by Sanger sequencing 
 
Location Polymorphism Controls Cases 
 
Exon 1 rs3762977 AA AG GG AA AG GG 
  329 102 6 136 39 4 
 
Exon 1 EX1+67G>C GG GC CC GG GC CC 
  432 4 0 176 1 0 
 
Exon 1 EX1+192C>G CC CG GG CC CG GG 
  438 0 0 179 1 0 
 
Exon 1 rs36216897 AA AG GG AA AG GG 
  418 15 0 175 3 0 
 
Exon 1 EX1-269G>A GG GA AA GG GA AA 
  424 9 0 178 2 0 
 
Exon 1 EX1-215T>G TT TG GG TT TG GG 
  432 0 0 178 1 0 
 
Exon 1 rs3917084 AA AG GG AA AG GG 
  404 22 0 172 6 0 
 
Intron 1 IVS+17C>T CC CT TT CC CT TT 
  402 30 0 163 15 0 
 
Exon 4 rs2303751 AA AG GG AA AG GG 
  NA NA NA 49 21 11 
 
Exon 4 EX4+89C>T CC CT TT CC CT TT 
  NA NA NA 87 1 0 
 
Intron 5 IVS5-105T>A TT TA AA TT TA AA 
  299 0 0 111 2 0 
 
Exon 6 EX6+96A>T AA AT TT AA AT TT 
  298 0 0 156 1 0 
 
Exon 6 EX6+483T>C TT TC CC TT TC CC 
  427 0 0 185 0 1 
 
Exon 6 rs41268421 GG GT TT GG GT TT 
  383 34 1 170 9 1 
 
Exon 6 rs1017 AA AT TT AA AT TT 





Table 3.3 ISL1 and risk of congenital heart disease in stage 1 US whites 
  
a) Single SNP associations 
Genotypes 
 
Controls [n (%)] 
 
Cases [n (%)] 
 




Stage 1     
 
rs3762977 
    
A/A 329 (75.3) 65 (79.3) 1.00  
A/G 102 (23.3) 15 (18.3) 0.74 (0.41 / 1.36) 0.338 
G/G 6 (1.4) 2 (2.4) 1.68 (0.33 / 8.55) 0.527 
  log-additive: 0.87 (0.52 / 1.47) 0.607 
 
IVS1+17C>T     
C/C 402 (93.1) 70 (85.4) 1.00  
C/T 30 (6.9) 12 (14.6) 2.30 (1.12 / 4.70) 0.023 
 
rs1017     
A/A 182 (42.8) 21 (25.3) 1.00  
A/T 192 (45.2) 43 (51.8) 1.94 (1.11 / 3.40) 0.020 
T/T 51 (12.0) 19 (22.9) 3.23 (1.61 / 6.46) 0.0009 
 
 log-additive: 1.81 (1.29 / 2.54) 0.0007 
 
b) Haplotype associations 
Haplotypes rs3762977 IVS1+17C>T rs1017 Frequency (%) OR [95% CI] P value 
 
1 A C A 0.622   1.00  
2 A C T 0.208 2.01 (1.35 / 2.99) 0.0006 
3 G C T 0.126 1.12 (0.64 / 1.95) 0.700 
4 A T T 0.038 3.30 (1.52 / 7.18) 0.0026 
 Global haplotype association   0.0008 
 




Table 3.4 Minor allele frequencies of 3 ISL1 SNPs in stage 2 US and Canadian cases 
 
SNP US Canada P value* 
rs3762977 0.128 0.109 0.756 
IVS1+17C>T 0.036 0.054 0.270 
rs1017 0.415 0.372 0.556 
* calculated by Fisher’s exact test
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Table 3.5 ISL1 and risk of congenital heart disease in stage 2 North American whites (US + Canada) 
 




Controls [n (%)] 
 
Cases [n (%)] 
 




rs3762977     
A/A 1128 (78.1) 281 (77.4) 1.00  
A/G 289 (20.0) 75 (20.7) 1.04 (0.78 / 1.38) 0.777 
G/G 28 (1.9) 7 (1.9) 1.00 (0.43 / 2.32) 0.993 
  log-additive: 1.03 (0.81 / 1.31) 0.815 
IVS1+17C>T     
C/C 1334 (92.3) 334 (92.0) 1.00  
C/T 111 (7.0) 29 (8.0) 1.04 (0.68 / 1.60) 0.843 
 
rs1017     
A/A 591 (40.9) 129 (35.3) 1.00  
A/T 672 (46.5) 177 (48.5) 1.21 (0.94 / 1.55) 0.144 
T/T 
 
182 (12.6) 59 (16.2) 1.49 (1.05 / 2.11) 0.027 
  log-additive: 1.22 (1.03 / 1.44) 0.022 
  
b) Haplotype associations 
Haplotypes rs3762977 IVS1+17C>T rs1017 Frequency (%) OR [95% CI] P value 
 
1 A C A 0.630   1.00  
2 A C T 0.211 1.33 (1.08 / 1.62) 0.0065 
3 G C T 0.119 1.09 (0.85 / 1.40) 0.502 
4 A T T 0.037 1.11 (0.71 / 1.72) 0.653 
 Global haplotype association   0.087 
 




Table 3.6 ISL1 and risk of congenital heart disease in stage 2 Dutch whites  
 




Controls [n (%)] 
 
Cases [n (%)] 
 




Stage 1     
rs3762977     
A/A 499 (77.6) 486 (78.1) 1.00  
A/G 139 (21.6) 124 (19.9) 0.92 (0.70 / 1.20) 0.528 
G/G 5 (0.8) 12 (2.0) 2.46 (0.86 / 7.04) 0.093 
  log-additive: 1.03 (0.81 / 1.31) 0.808 
IVS1+17C>T     
C/C 571 (88.8) 560 (91.2) 1.00  
C/T 72 (11.2) 51 (8.3) 0.72 (0.50 / 1.05) 0.091 
T/T 0 (0) 3 (0.5) NA 0.975 
  log-additive: 0.82 (0.57 / 1.17) 0.277 
rs1017     
A/A 204 (31.7) 229 (36.4) 1.00  
A/T 319 (49.6) 297 (47.1) 0.83 (0.65 / 1.06) 0.134 
T/T 120 (18.7) 104 (16.5) 0.77 (0.56 / 10.7) 0.117 
 
b) Haplotype associations  
Haplotypes rs3762977 IVS1+17C>T rs1017 Frequency (%) OR [95% CI] P value 
 
1 A C A 0.668   1.00  
2 A C T 0.165 0.96 (0.73 / 1.25) 0.762 
3 G C A 0.064 1.01 (0.72 / 1.42) 0.958 
4 G C T 0.052 0.95 (0.62 / 1.45) 0.798 
5 A T A 0.025 1.04 (0.60 / 1.82) 0.887 
6 A T T 0.025 0.58 (0.31 / 1.07) 0.082 
 Global haplotype association   0.473 
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Table 3.7 ISL1 haplotype association with risk of CHD in stage 2 whites (US, Canada, Netherlands) 
 
Haplotypes rs3762977 IVS1+17C>T rs1017 Frequency (%) OR [95% CI]* P value* 
 
1 A C A 0.649   1.00  
2 A C T 0.190 1.18 (1.00 / 1.39) 0.0485 
3 G C T 0.093 1.04 (.084 / 1.28) 0.722 
4 A T T 0.033 0.86 (0.61 / 1.23) 0.423 
5 G C A 0.025 1.08 (0.77 / 1.52) 0.655 
 Global haplotype association   0.00003 
 
Rare estimated haplotypes (cumulative frequency = 0.010) not shown. 
 
* Controlling for geographical region (North American vs. Dutch) 
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Table 3.8 Summary ISL1 haplotype association with risk of CHD in all whites (stage 1 & stage 2) 
 
Haplotypes rs3762977 IVS1+17C>T rs1017 Frequency (%) OR [95% CI] P value 
 
1 A C A 0.645   1.00  
2 A C T 0.192 1.27 (1.09 / 1.48) 0.0018 
3 G C T 0.098 1.07 (0.88 / 1.30) 0.5068 
4 A T T 0.034 1.04 (0.75 / 1.44) 0.8216 
5 G C A 0.022 1.10 (0.78 / 1.53) 0.5928 
 Global haplotype association   0.000004 
 
Rare estimated haplotypes (cumulative frequency = 0.0099) not shown. 
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Table 3.9 ISL1 associations with risk of HLHS and D-TGA in white populations 
 
 
 Stage 1 Stage 2* Combined† 
 OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
rs1017 2.04 (1.17 – 3.56) 0.012 1.36 (0.96 – 1.94) 0.086 1.48 (1.08 – 2.04) 0.016 
A-C-T 2.27 (1.22 – 4.24) 0.010 1.35 (0.90 – 2.04) 0.15 1.62 (1.12 – 2.35) 0.0099 
* Analyses controlled for center 
† Analyses controlled for center and stage
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Table 3.10 ISL1 and risk of congenital heart disease in stage 1 US blacks/African Americans  
 




Controls [n (%)] 
 
Cases [n (%)] 
 




Stage 1     
rs3762977     
A/A 46 (67.7) 21 (45.7) 1.00  
A/G 20 (29.4) 21 (45.7) 2.30 (1.03 / 5.12) 0.042 
G/G 2 (2.9) 4 (8.6) 4.38 (0.74 / 25.8) 0.103 
  log-additive: 2.21 (1.15 / 4.23) 0.017 
IVS1+17C>T     
C/C 104 (99.0) 46 (100) 1.00  
C/T 1 (1.0) 0 (0) NA 0.507 
rs1017     
A/A 18 (22.0) 10 (21.7) 1.00  
A/T 37 (45.1) 19 (41.3) 0.92 (0.36 / 2.39) 0.871 
T/T 
 
27 (32.9) 17 (37.0) 1.13 (0.42 / 3.03) 0.803 
  log-additive: 1.08 (0.66 / 1.76) 0.756 
 
b) Haplotype associations 
Haplotypes rs3762977 IVS1+17C>T rs1017 Frequency (%) OR [95% CI] P value 
 
1 A C A 0.443   1.00  
2 A C T 0.336 0.65 (0.34 / 1.24) 0.195 
3 G C T 0.218 1.99 (1.02 / 3.87) 0.044 
 Global haplotype association   0.051 
 




Table 3.11 ISL1 and risk of congenital heart disease in stage 2 US blacks/African Americans  
 




Controls [n (%)] 
 
Cases [n (%)] 
 




Stage 1     
rs3762977     
A/A 1235 (66.9) 31 (63.3) 1.00  
A/G 540 (29.3) 15 (30.6) 1.11 (0.59 / 2.07) 0.751 
G/G 70 (3.8) 3 (6.1) 1.71 (0.51 / 5.72) 0.386 
  log-additive: 1.20 (0.74 / 1.95) 0.457 
IVS1+17C>T     
C/C 1803 (97.7) 49 (100) 1.00  
C/T 42 (2.3) 0 (0) NA 0.564 
rs1017     
A/A 476 (25.8) 11 (22.5) 1.00  
A/T 901 (48.8) 22 (44.9) 1.06 (0.51 / 2.20) 0.883 
T/T 
 
468 (25.4) 16 (32.6) 1.48 (0.68 / 3.22) 0.324 
  log-additive: 1.23 (0.83 / 1.83) 0.306 
 
b) Haplotype associations 
Haplotypes rs3762977 IVS1+17C>T rs1017 Frequency (%) OR [95% CI] P value 
 
1 A C A 0.496   1.00  
2 A C T 0.308 1.29 (0.82 / 2.03) 0.270 
3 G C T 0.180 1.28 (0.75 / 2.19) 0.359 
 Global haplotype association   0.464 
 




Table 3.12 Summary ISL1 haplotype association with risk of CHD in all blacks/African Americans (stage 1 & stage 2) 
 
Haplotypes rs3762977 IVS1+17C>T rs1017 Frequency (%) OR [95% CI] P value 
 
1 A C A 0.492   1.00  
2 A C T 0.310 1.16 (0.81 / 1.66) 0.427 
3 G C T 0.183 1.58 (1.08 / 2.31) 0.019 
 Global haplotype association   0.343 
 
Rare estimated haplotypes (cumulative frequency = 0.015) not shown. 
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Figure 3.1 Diagnosis distribution in stage 1 and stage 2 case-control studies. Cases 
were chosen a priori to represent a wide variety of developmental phenotypes that include 
developmental structures aberrantly formed as derivatives of the secondary heart field. These 
diagnostic choices were informed from lineage tracing analyses of Isl1+ progenitor cells in 





Figure 3.2 Ethnic distribution of cases and controls by cluster analysis. The first two 
principal components from a principal components analysis utilizing all SNPs on 
chromosome 5 that are contained within the Illumina HumanHap550 array are plotted for 
a) stage 1 cases of known ethnicity, where PC1≤0.025 captures white cases and 
PC1>0.025 captures black/African American cases; b) stage 2 cases of unknown 
ethnicity, where PC1≤0.025 defines white cases and PC1>0.025 defines black/African 
American cases; c) stage 1 controls of known ethnicity, where PC1≤0.0059 captures 
white controls and PC1>0.0059 captures black/African American controls; b) stage 2 
cases of unknown ethnicity, where PC1≤0.0059 defines white controls and PC1>0.0059 





Figure 3.3 Stage 1 ISL1 SNP associations with CHD on chromosome 5. Analysis of 
SNP data within and surrounding ISL1 in stage 1 yielded 8 SNPs that were significantly 
associated with CHD in an ethnically heterogeneous US population. ORs, 95%CIs and P 
values significant at = 0.05 are depicted in black. Non-significant ORs, 95% CIs and P 
values are depicted in grey. The yellow highlighted region indicates the location of ISL1 
on chromosome 5. Labeled SNPs: (a) rs6867206, (b) rs4865656, (c) rs6869844, (d) 




Figure 3.4 Chromosome 5 variation in the ISL1 region. The location of ISL1 on chromosome 5 (Build 36) is depicted, where exons 
of the ISL1 gene are depicted as shaded boxes, the 5’ UTR and 3’ UTR are depicted as white boxes, and introns are represented as 
black lines. The three SNPs within ISL1 studied in stage 1 and stage 2 are depicted with respect to their location in the gene. The six 




Figure 3.5 Stage 2 ISL1 SNP associations with CHD on chromosome 5.  Analysis of 
SNP data within and surrounding ISL1 in stage 2 US whites yielded 10 SNPs that were 
significantly associated with CHD in an initial analysis of an ethnically heterogeneous 
US population. ORs, 95%CIs and P values significant at = 0.05 are depicted in black. 
Non-significant ORs, 95% CIs and P values are depicted in grey. The yellow highlighted 
region indicates the location of ISL1 on chromosome 5. Labeled SNPs: a) rs6867206, b) 
rs4865656, c) rs6869844, d) rs2115322, e) rs6449600, f) rs3762977 †, g) IVS1+17C>T 






Figure 3.6 ISL1 haplotypes and risk of congenital heart disease by race/ethnicity. a) 
The A-C-T risk haplotype in white stage 1 (US) and stage 2 (US, Canada, Netherlands) 
populations. Odds ratios (95% CIs) for each stage are denoted by black boxes (gray 
lines). Summary OR estimates are represented by black diamonds, where diamond width 
corresponds to 95% CI bounds. Box and diamond heights are inversely proportional to 
precision of the OR estimate. b) The G-C-T risk haplotype in black/African American 




Figure 3.7 ANCESTRYMAP admixture estimation using 26 Ancestral Informative 
Markers. The distribution of estimated percent European ancestry for a) all stage 1 US 
subjects of known ethnicity (n=650), b) stage 1 US whites (n=251), c) stage 2 US 
blacks/African Americans (n=399), and d) stage 2 US subjects of unknown ethnicity 
(n=3610). 65% cutoff is represented by a red line. Individuals above 65% European 













Survivors living with congenital heart disease (CHD) are a large and growing 
population, with an estimated 1.3 million people currently living with CHD in the United 
States (Hoffman et al., 2004).  These individuals have been closely observed to 
understand clinical outcomes related to their specific cardiac defects, with particular 
emphasis on mortality, additional heart complications, overall functional status, and 
quality of life (Connor et al., 2004; Hickey et al., 2009; Schultz and Wernovsky, 2005; 
Verheugt et al., 2008).  Despite these extensive studies investigating CHD-related 
outcomes, the impact of other chronic diseases, such as childhood cancer, experienced by 
this patient population is not well understood.   
Several genetic disorders are associated with both cardiac defects and an 
increased risk of pediatric cancers.  Children with Down syndrome (trisomy 21) are at a 
higher risk of developing acute myeloid leukemia (AML) or acute lymphoblastic 
leukemia (ALL) than the general population (0-4 years: Standardized incidence ratio 
(SIR) (95% CI) = 56 (38 -81); 5-29 years: SIR (95% CI) = 10 (4 - 20)) (Freeman et al., 
1998).  Approximately 44% of Down syndrome children also have various congenital 
heart defects, most of which are atrioventricular (45%) or ventricular septal defects 
(35%) (Roizen and Patterson, 2003).  The majority of children with Noonan and Costello 
syndromes also have characteristic cardiac phenotypes, such as pulmonary valve stenosis, 
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hypertrophic cardiomyopathy, and atrial tachycardia (Denayer et al., 2008; Tartaglia and 
Gelb, 2005).  These disorders are caused by mutations in the RAS pathway (Gripp, 2005; 
Tartaglia and Gelb, 2005), a set of genes commonly found to be mutated in multiple 
cancer types (Bos, 1989; Davies et al., 2002).  Children with Noonan syndrome are at an 
increased risk of juvenile myelomonocytic leukemia (JMML) and rhabdomyosarcoma 
(Denayer et al., 2008), while children with Costello syndrome are at an increased risk of 
rhabdomyosarcoma, neuroblastoma, and bladder carcinoma (Denayer et al., 2008; Gripp, 
2005). 
These genetic syndromes provide evidence that events occurring early in 
development, such as chromosomal abnormalities or mutations, can result in both 
congenital anomalies and an increased susceptibility to cancer.  We hypothesize that this 
phenomenon may extend beyond these currently described disorders, affecting a larger 
population of children with non-syndromic birth defects.  Indeed, associations between 
various birth defects and childhood cancers have been identified.  A large population-
based study of childhood cancers in Great Britain found congenital malformations in 
4.4% of children with solid tumors and 2.6% of children with leukemia or lymphoma 
(Narod et al., 1997).  Furthermore, several large cohort studies of children with 
congenital anomalies in Toronto, Northern England, Norway, and Sweden have identified 
associations between subsets of birth defects and pediatric cancers, including hepatic 
cancers among children with digestive system anomalies, lymphomas and bone tumors 
among children with musculoskeletal deformities, and kidney tumors among children 




Although these studies provide evidence for an association between 
developmental abnormalities and cancer risk, causal links have yet to be identified.  
Studying cancer incidence among children with specific subsets of birth defects may 
provide a way to unravel the complex biology underlying these relationships, particularly 
considering that most of the excess cancers identified in these studies were related to only 
specific types of birth defects.   Congenital heart disease is an ideal candidate for such an 
analysis, as most cases of CHD are not explained by known risk factors such as maternal 
exposures or chromosomal abnormalities.  The relationship between childhood cancer 
and congenital heart disease has not previously been investigated, yet this would provide 
an opportunity to gain significant insight into the etiologies of both sets of diseases.  In 
this chapter, I investigate this relationship and demonstrate an excess of pediatric cancers 
in a large, hospital-based cohort of children with congenital heart disease. 
 
4.2 Subjects and methods 
4.2.1 Study design 
 To investigate the relationship between childhood cancers and congenital heart 
disease, we conducted a retrospective cohort study of CHD at the Children’s Hospital of 
Philadelphia.  The source population for this study consists of any child with a congenital 
heart defect requiring operative repair at CHOP between the ages of 0 and 18 years.   
Although the majority of individuals in this population reside in Pennsylvania and New 
Jersey (77.7%), this is not a geographically restricted source population since patients 
from across the country are referred to the Cardiac Center at CHOP.   Follow-up for the 
diagnosis of any malignant neoplasm was complete through Jul 22, 2009 when data were 
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ascertained through the CHOP cancer registry.  Incidence rates of cancer were first 
calculated within the CHOP cohort, taking into consideration potential risk factors such 
as genetic syndromes and diagnostic radiation exposure.  We then compared the observed 
number of cancers in this cohort to the number of expected cancers based on US pediatric 




Congenital heart disease cases were ascertained for this retrospective cohort study 
at the Children’s Hospital of Philadelphia on a protocol approved by the Institutional 
Review Boards of CHOP and the University of Michigan.  Cases were selected for 
inclusion in the study if they had undergone operative repair of a cardiac defect from 
January 1, 2001 to July 22, 2009 at the CHOP Cardiac Center.  Subjects also had to be 18 
years of age or less at the time of operative repair.  Cases were ineligible for the study if 
the primary or secondary indication for operation at the time of ascertainment was not 
classified as a congenital heart defect (Table 4.1). 
 
4.2.3 Identification of incident cancers 
Incident cancers were identified from the CHOP cancer registry at the end of 
follow-up.  All patients in the CHOP cancer registry on July 22, 2009 were queried by 
medical record number and date of birth to identify patients from the CHD cohort. Date 
of cancer diagnosis and cancer histology / behavior were obtained for each member of the 
CHD cohort also present in the CHOP cancer registry.  Only malignant diagnoses were 
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classified as incident cancers.  
 
4.2.2 Data collection 
Collection of demographic and clinical information for eligible CHD cases was 
performed at the Children’s Hospital of Philadelphia.  Medical records were reviewed for 
demographic variables including date of birth, sex, race, and state of residence at the time 
of operation.  Clinical information obtained from medical records included date of 
operation, diagnoses made at the time of operation, operation type, and genetic syndrome 
or other chromosomal abnormality. 
Data from diagnostic radiation exams performed at the Children’s Hospital of 
Philadelphia during the follow-up period were obtained from the Department of 
Radiology at CHOP.  These data included plain films, computerized tomography (CT) 
scans, fluoroscopy procedures, nuclear medicine exams, and the corresponding date of 
administration for each exam.  Radiation exposure in millisieverts (mSv) resulting from 
each exam was calculated using a comprehensive radiology look-up-table, which is based 
on the age at which the exam was administered.   
Additionally, data from all cardiac catheterizations performed at CHOP during the 
follow-up period were obtained from the Cardiology Department.  These data included 
the date of exam, weight of the patient at the time of the exam (kg), and duration of the 
exam (minutes).  Radiation exposure in millisieverts (mSv) resulting from each 
catheterization was calculated using a two-stage approach (Table 4.2).  First, linear 
regression was used to estimate the relationship between fluoroscopy time and measured 
dose-area product (µGy•m2) using available data from CHOP patients for whom dose-
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area product was measured directly. The estimates from these models were then used to 
calculate dose-area product for each patient based on fluoroscopy time and weight at the 
time of exam.   Dose-area product was then converted to total effective radiation dose 
(mSv) using a conversion factor calculated from previous radiologic phantom studies 
(ATOM®, Computerized Imaging Reference Systems, Inc., Norfolk, VA) performed at 
CHOP in conjunction with a radiation physicist.   
For patients that developed cancer during the follow-up period, we excluded any 
exam administered from three months prior to the date of cancer diagnosis to the end of 
follow-up.  Cumulative radiation exposure (mSv) for each subject in the cohort was 
calculated by summing the individual exposures received from each exam, including any 
plain films, CT scan, fluoroscopy procedures, nuclear medicine exams, or cardiac 
catheterizations.   
 
4.2.3 Statistical methods 
All statistical analyses were performed in SAS (version 9.2) and graphics were 
prepared in R (version 2.10.1).  Descriptive statistics were calculated for categorical 
variables using frequency tables and were calculated for continuous variables using the 
means procedure.  Radiation exposure was examined as both a continuous variable and a 
categorical variable.  Densities for radiation exposure were estimated using the density 
function in the stats R package. 
Each participant contributed person-years to this analysis, calculated separately 
for cancer and non-cancer cases.  For CHD patients that did not develop cancer during 
the follow-up period, person-years were calculated from date of birth to the end of 
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follow-up.  For CHD patients that were identified to have developed cancer during the 
follow-up period, person-years were calculated from date of birth to the date of cancer 
diagnosis.  
Rates of cancer within the cohort were calculated by Poisson regression using the 
genmod procedure.  Pediatric cancer rates by five-year age intervals were obtained from 
SEER using data from 2000-2006 (http://seer.cancer.gov/statistics/), and these rates were 
used to calculate the expected numbers of cancer in this cohort using the means 
procedure.  Age-standardized incidence ratios, 95% confidence intervals, and 
corresponding p-values were calculated using Poisson regression as implemented by the 
genmod procedure. Sex, genetic syndrome status, and radiation exposure were included 
as covariates in these models when appropriate. 
 
4.3 Results 
4.3.1 CHOP cohort 
To investigate the epidemiology of pediatric cancers among children diagnosed 
with congenital heart disease, we conducted a retrospective cohort study of CHD at the 
Children’s Hospital of Philadelphia (CHOP).  A total of 5,162 patients underwent at least 
one operation at the CHOP Cardiac Center from January 1, 2001 to July 22, 2009.  Of 
this total patient population, 4,805 (93.1%) patients underwent repair for a congenital 
heart defect and 4,523 (87.6%) children were also 0-18 years of age at the time of 
operation. 
Among these 4,523 eligible CHD patients, children were nearly equally 
distributed among age categories, with a slightly higher proportion of neonates (38.2%) 
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compared to infants (29.2%) and children (32.6%) (Table 4.3).  The median age at 
operation was 0.25 years (mean = 2.5, standard deviation (SD) = 4.5), reflecting that most 
of the cardiac defects in this cohort required operative repair early in life.  Children in the 
cohort were slightly more likely to be male (54.6%) compared to female (45.3%).  Race 
was missing for a substantial proportion of this cohort (34.7%); among those with known 
race, children were most likely to be white (66.7%) or black/African American (19.9%).   
The most common congenital heart defects in this cohort were patent ductus 
arteriosus, ventricular septal defects, tetralogy of Fallot, hypoplastic left heart syndrome, 
coarctation of the aorta, and d-transposition of the great arteries (Table 4.1).  While the 
CHD diagnoses observed among these children represented a range of moderate to severe 
defects, most were severe and required operative repair in early infancy.  Although mild 
or moderate defects that present later in life or do not require operative repair at all are 
potentially associated with cancer development, these defects are not captured in this 
cohort. 
The presence of genetic syndromes or other chromosomal abnormalities in these 
children was of particular interest in this study because of the association between 
pediatric cancer incidence and some genetic syndromes.  Consistent with current 
estimates of the proportion of CHD attributed to chromosomal abnormalities in the 
literature (Pierpont et al., 2007), 13.8% of all subjects had a genetic syndrome or other 
chromosomal abnormality (Table 4.4).  The most common syndromes were Down 
syndrome (45.0%) and DiGeorge syndrome (13.0%).  An additional 14.5% of these 625 
children had dysmorphic features but no identified genetic syndrome.  Among the 
identifiable genetic syndromes were several that are associated with increased rates of 
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cancer, including Down syndrome (trisomy 21) (Freeman et al., 1998),  Hirschprung 
disease (Sijmons et al., 1998), LEOPARD syndrome (Schrader et al., 2009), 
neurofibromatosis (Asthagiri et al., 2009; Sorensen et al., 1986), Noonan syndrome 
(Denayer et al., 2008), trisomy 18 (Schnater et al., 2003), and Turner syndrome 
(Schoemaker et al., 2008).  
 
4.3.2 Pediatric cancer incidence 
 Among all 5,162 children seen at the CHOP Cardiac Center from 01/01/2001 to 
07/22/2009, 57 were identified as diagnosed with cancer within the CHOP cancer registry 
by the end of follow-up.  Four of these patients were older than 18 years at the time of 
their cardiac operation and were excluded from our analyses.  The primary indications for 
operation at the Cardiac Center for 31 of these 57 cancer patients were non-CHD 
diagnoses, including cardiac tumors (19.4%), lung diseases (19.4%), mediastinal or 
pleural diseases (41.9%), and heart or lung transplants (12.9%).  Although excluded from 
our subsequent analyses, we observed that 4 of the 24 patients that underwent heart or 
lung transplantation developed cancer during follow-up, three with lymphoproliferative 
diseases and one with a rhabdomyosarcoma.  This is consistent with the observation that 
patients who have undergone solid organ transplantation have a 5- to10-fold increase in 
cancer risk (Gross et al., 2010), the most common being posttransplant 
lymphoproliferative disease (PTLD).    
We next restricted our analysis to include only the 4,523 eligible patients 
comprising the CHD cohort, limited to those children who had undergone operative 
repair of a congenital heart defect at the age of 18 years or less.  A total of 23 children 
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were diagnosed with cancer during the follow-up period, corresponding to an incidence 
rate of 70 per 100,000 person-years.  Compared to the expected number of cancers in this 
cohort based on SEER-estimated rates of pediatric cancer in the United States, this 
represents a 3.72-fold increase in pediatric cancer incidence (Standardized Incidence 
Ratio (SIR) = 3.72, 95% CI = 1.53 – 9.04, p = 0.0037).  
 The locations and histologies of these incident cancers were variable, including 
brain and other nervous system tumors, hematological tumors, a neuroendocrine tumor, a 
soft tissue tumor, and other solid tumors (Table 4.5).  The types of cardiac defects 
observed among these children were qualitatively similar to the distribution of CHD in 
the total cohort.  Although not statistically significantly different, children who developed 
cancer were followed on average for 6 months longer than children who did not develop 
cancer during follow-up (p=0.31).  Children diagnosed with cancer were also slightly 
older at the time of operative repair for their cardiac defect compared to cancer-free CHD 
patients and were more likely to be female (Table 4.3).  The rate of cancer among 
females was not significantly different compared to males (Hazard ratio (HR) = 1.35, 
95% CI 0.60 – 3.06, p=0.47) (Table 4.6).  
 To understand the relationship between known chromosomal abnormalities and 
cancer development in this cohort, we next examined the distribution of tumors by 
genetic syndrome diagnoses (Figure 4.1).  Almost half (44.5%) of these 23 cancer 
patients had a genetic syndrome, corresponding to an estimated incidence rate of 250 per 
100,000 person-years among children with any genetic syndrome (Table 4.6).  The most 
common syndrome among these 10 children was Down syndrome, which was diagnosed 
in 7 patients with cancer and was associated exclusively with hematological cancers 
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including precursor B-cell leukemia, lymphoproliferative disease, and myeloproliferative 
disease (Table 4.5, Figure 4.1).  The number of cancers among all 281 children with 
Down syndrome was 22.83 times higher (95% CI 0.61 – 849.50, p=0.09) than expected 
based on US pediatric cancer rates.   Additionally, one patient with Turner syndrome 
developed a neuroblastoma, one patient with monosomy 7 developed myelodysplastic 
syndrome, and one patient with dysmorphic features developed a cranial teratoma.  While 
not statistically significant, the number of cancers among the remaining 344 children with 
genetic syndromes other than Down syndrome was 6.07 times higher (95% CI 0.30 – 
123.22, p=0.24) than expected.  Considering all genetic syndromes together, there was a 
12.49-fold increase (95% CI 1.28 – 121.74, p=0.03) in the number of cancers among all 
625 children with a genetic syndrome compared to the 5 cancers expected based on US 
rates (Table 4.7). 
 An additional 13 children without an identifiable genetic syndrome were also 
diagnosed with cancer at CHOP, corresponding to an incidence rate of 49 per 100,000 
person-years (Table 4.6).  In general, the proportions of cancer types observed in this 
group were consistent with the distribution of pediatric cancers as reported by SEER, 
where hematological cancers were the most common (38.5%) followed by brain or 
central nervous system (CNS) tumors (30.8%).  In addition, an embryonal 
rhabdomyosarcoma was diagnosed in a child with dilated cardiomyopathy and a teratoma 
was diagnosed in a child with patent ductus arteriosus; both teratoma and 
rhabdomyosarcoma are relatively common pediatric tumors.  Two uncommon pediatric 
tumors were also observed: one paraganglioma and one hepatoblastoma.  Together, these 
13 cancers represent a 2.41-fold increase (95% CI 0.88 – 6.60, p=0.086) in the number of 
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cancers expected among children without a genetic syndrome (Table 4.7).  Children with 
any genetic syndrome had a higher rate of cancer (Rate ratio (RR) = 4.13, 95% CI 1.71 – 
9.96, p=0.0016) and a higher SIR (SIR ratio = 5.18, 95% CI 0.43 – 62.32, p=0.20) 
compared to children with no genetic syndromes.  However, these data provide evidence 
that there is still a substantial increase in pediatric cancer rates among CHD patients that 
is not attributable to identifiable genetic syndromes alone. 
 Exposure to diagnostic radiation was also of interest in this study as a potential 
risk factor for cancer development.  Data from 132,208 diagnostic radiation exams were 
available from the CHOP Radiology and Cardiology departments for 4,162 children in 
the cohort.  The types of exams represented in this data set include plain films, CT 
exams, nuclear medicine exams, fluoroscopy procedures, and cardiac catheterization.  We 
found that the total effective radiation exposure in this cohort was low but quite variable 
(Figure 4.2).  The median exposure in the cohort was 1.01 millisieverts (mSv), although 
dosages ranged between 0.01 mSv and 518.72 mSv.  The median exposure in this cohort 
is comparable to the estimated average annual effective dose in the U.S. population of 1.2 
mSv. 
 Radiation exposure was marginally higher among the 14 cancer patients with 
available radiation data compared to the remaining patients in the cohort, though this 
increase was not statistically significant (Wilcoxon p = 0.62) (Figure 4.2).  Within the 
cohort, the rate of pediatric cancer increased by 0.4% for every one millisievert increase 
in diagnostic radiation (RR=1.004, 95% CI 0.9935 – 1.1957, p=0.42).  Consistent with 
this analysis, the number of cancers among children who received greater than 1.01 mSv 
of radiation was 2.88 times greater (95% CI 0.74 – 11.27, p=0.13) than the number 
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expected based on US pediatric cancer rates, while the number of cancers among children 
who received less than 1.01 mSv of radiation was 1.99 times greater (95% CI 0.50 – 7.94, 
p=0.33) than expected.  This difference in the SIRs was not statistically significant (SIR 
ratio = 1.45, 95% CI 0.21 – 10.10, p=0.71).   These data provide evidence for a 
previously unrecognized association between CHD and childhood cancer that is not fully 
accounted for by genetic syndromes or radiation exposure.  
 
4.4 Discussion 
We have identified an almost 4-fold increase in the rate of cancer among children 
with congenital heart disease.  Down syndrome and other genetic syndromes were 
strongly associated with cancer risk, but there remains an unexplained 2.4-fold increase 
in risk among children without any identifiable genetic disorders (p = 0.086). 
Investigating the environmental exposures and genetic abnormalities that are found 
among the CHD patients that developed cancer may provide significant insight into the 
causes of these two sets of diseases.  
Radiation exposure was not significantly associated with an increased rate of 
cancer in this study.  The relationship between diagnostic radiation and childhood cancer 
risk is unclear, and studies are inconclusive about the dose, duration, and the induction 
period between radiation exposure and tumorigenesis in childhood.  A classic study 
reported an increased risk of brain tumors among individuals treated with radiation for 
tinea capitis in childhood, although the overall dosage was high (1-2Gy) and it is 
important to note that cancers were not identified until an average of 30 years after 
exposure (Sadetzki et al., 2005).  Another study investigating postnatal x-ray exposure 
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and childhood cancer risk found no increase in cancer rates, but the average exposure was 
7 μSv, about 1000-fold less than the median exposure in the Sadetzki study (Hammer et 
al., 2009).  Finally, a study of cancer following cardiac catheterization found a 2.3-fold 
increase in cancer rates, where cancers were identified from 5 to 38 years after exposure 
(Modan et al., 2000).  Considering these findings, it is not altogether surprising that we 
cannot detect an excess of cancers attributable to radiation exposure given that most 
children were exposed to low levels of radiation and were followed on average for only 
4.5 years.  We may also simply have insufficient power to detect a meaningful increase in 
cancer risk if the true effect is small.  Using a Poisson model to calculate power with 
α=0.05, we had only 7.5% power to detect a 1.44-fold difference in pediatric cancer rates 
between children with less than vs. greater than median radiation.  Using this same 
model, we had only 8.9% power to detect an SIR of 2.78 and 9.6% power to detect an 
SIR of 3.02 among children with less than and greater than median radiation, 
respectively. Long term follow-up of the CHOP cohort is warranted, especially given the 
exceptionally high quality radiation dosimetry data available and clinical data for these 
children. 
One limitation of this study is that we had limited sensitivity to identify cancers 
diagnosed at institutions other than CHOP.  Approximately 22.3% of the CHD cohort 
resided outside of Pennsylvania or New Jersey at the time of their CHD operation, and it 
is likely that cancers within this group would not have been captured by the CHOP 
cancer registry unless these patients returned to CHOP for long-term follow-up.  This 
type of misclassification would be expected to result in underestimation of the actual 
number of incident cancers among children in this cohort.  Thus, the results presented in 
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this dissertation are most likely underestimates of the true rates of pediatric cancer among 
children with CHD.  
To explore this issue given the available data, we performed a subset analysis 
where we restricted the cohort to children who resided in Pennsylvania or New Jersey at 
the time of their CHD operation.  The results of this analysis were qualitatively similar to 
those described above, but with limited power to detect associations due to the decrease 
in sample size.  Among the 3,509 children that resided in Pennsylvania or New Jersey at 
the time of their CHD operation, 16 developed cancer during the follow-up period, 
corresponding to a 3.35-fold increase in the rate of cancer compared to the general 
population (SIR=3.35, 95% CI 1.21 – 9.32, p=0.020).  Children with any genetic 
syndrome had cancer rates 7.91 times higher than children with no genetic syndrome 
(HR=7.91, 95% CI 2.97 – 21.08, p < 0.0001). Correspondingly, children with genetic 
syndromes had rates of cancer 14.94 times higher than the general population 
(SIR=14.94, 95% CI 0.94 – 237.52, p = 0.055). While not statistically significant, 
children without genetic syndromes had a 1.89-fold higher rate of cancer than the general 
population (SIR=1.89, 95% CI 0.58 – 6.13, p 0.029). 
A related issue is that while the CHD diagnoses observed among these children 
represented a range of moderate to severe defects, most were severe and required 
operative repair in early infancy.  Although mild or moderate defects that present later in 
life or do not require operative repair at all are potentially associated with cancer 
development, these defects are not captured in this cohort.  The estimates in this study 
would be biased if the association between cancer and CHD is substantially different in 
magnitude between children with severe defects compared to children with milder 
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defects.  Given this limitation, the estimates in this study are only generalizable to 
children with severe CHD requiring operative repair, as the association between CHD 
and cancer risk among children with mild CHD not requiring operative repair remains 
unknown. 
The cohort experienced a short follow-up period, with an average follow-up time 
of 4.5 years.  This has several implications.  First, it is likely that some children in the 
cohort will develop cancer after the end follow-up in this study, particularly neonates and 
infants who could be no older than 10 years at the end of follow-up.  Second, those 
cancers that did develop are more likely to be attributed to prenatal exposure or genetic 
abnormalities.  The latent period for cancers attributable to exposures such as postnatal 
diagnostic radiation is likely to be longer than the average follow-up time, given the 
discussion of radiation and cancer risk above. 
We identified a higher rate of cancer among children with genetic syndromes, 
with a particularly strong association observed between Down syndrome and risk of 
hematological malignancies.  This is consistent with the known association between 
chromosomal abnormalities and cancer risk.  However, it is interesting to note that cancer 
was only identified among children with Down syndrome, Turner syndrome, and 
monosomy 7 developed cancer in this study even though an additional 22 children had a 
disorder known to be associated with tumor development.  For example, none of the 10 
patients with Noonan syndrome were diagnosed with cancer over the approximately 4.5 
person-years of cumulative follow-up, with the oldest patient now 25 years of age.  This 
is certainly influenced by the limited power of our study to detect an increased risk for 
subtypes of genetic syndromes based on: 1) overall rarity of childhood cancer, even 
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among a high-risk group, 2) the short follow-up period, and 3) incomplete ascertainment 
of incident cancers as discussed above.  
Another limitation is that the estimates of childhood cancer rates in this study may 
be affected by the types of defects observed in the CHOP cohort.  Since children were 
ascertained on the basis of operative repair for their CHD, mild or moderate defects that 
do not require an operation were not captured.  However, it is possible that these defects 
are also related to childhood cancer risk and should be included when investigating the 
relationship between CHD and pediatric cancers.  Nonetheless, this study provides strong 
evidence for an increase in cancer risk among children with CHD, warranting further 
investigation to understand the basis for this relationship. 
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Table 4.1 Congenital heart defects of patients in CHOP cohort (n=4523) 
CHD diagnosis* n (%) 
AI 64 (1.42) 
AP window 9 (0.20) 
ASD 280 (6.20) 
AVSD  304 (6.73) 
Aberrant subclavian artery 3 (0.07) 
Ao aneurysm 21 (0.46) 
Ao dissection 1 (0.02) 
Ao stenosis  122 (2.70) 
Aortic arch hypoplasia 12 (0.27) 
Arrhythmia  190 (4.20) 
Bilateral SVC 4 (0.09) 
CCAVC, unbalanced 4 (0.09) 
CDH  2 (0.04) 
CoA 281 (6.22) 
Conduit failure 6 (0.13) 
Cor triatriatum 10 (0.22) 
Coronary artery anomaly 70 (1.55) 
D-TGA 256 (5.66) 
DCM 34 (0.75) 
DCRV 30 (0.66) 
DILV 49 (1.08) 
DIRV 1 (0.02) 
DOLV 3 (0.07) 
DORV  109 (2.41) 
Ebstein’s anomaly 12 (0.27) 
HCM 20 (0.44) 
HLHS 399 (8.83) 
Heart failure 21 (0.46) 
IAA 48 (1.06) 
L-TGA 5 (0.11) 
MR  41 (0.91) 
MS 11 (0.24) 
MV abnormality 3 (0.07) 
MV atresia 11 (0.24) 
PA 46 (1.02) 
PA stenosis 14 (0.31) 
PA/VSD 46 (1.02) 
PAPVC 27 (0.60) 
PDA  703 (15.56) 
PHTN 21 (0.46) 
PI 6 (0.13) 
PS  4 (0.09) 
PV stenosis 19 (0.42) 




Table 4.1 continued 
PVD 1 (0.02) 
Pericardial disease 11 (0.24) 
Pulmonary valve disease  5 (0.11) 
RVOTO 2 (0.04) 
Single ventricle, other 65 (1.44) 
TAPVC 49 (1.08) 
TOF 400 (8.85) 
TOF/APV 12 (0.27) 
Tracheal stenosis 5 (0.11) 
Tricuspid atresia 51 (1.13) 
Tricuspid stenosis 9 (0.20) 
Tricuspid valve disease 15 (0.33) 
Truncus arteriosus 63 (1.39) 
VSD  406 (8.96) 
Vascular Ring 104 (2.30) 













Table 4.2 Cardiac catheterization conversions from fluoroscopy time to effective 





Effective radiation dose† 
(mSv) 
≤ 5 (MIN†) x 12.79   + 64.11 (µGy•m2) x 0.02072 
(5-15] (MIN) x 30.95   + 171.14 (µGy•m2) x 0.00914 
(15-30] (MIN) x 67.36   + 642.18 (µGy•m2) x 0.0068 
(30-60] (MIN) x 249.46 + 332.99 (µGy•m2) x 0.00206 
> 60 (MIN) x 468.41 + 607.72 (µGy•m2) x 0.00175 
* Models estimated by linear regression  




Table 4.3 Demographic and clinical characteristics of CHOP CHD cohort (n=4,523) 










Age at operation (years) Mean=2.5 SD=4.5 Mean=2.5 SD=4.5 Mean=4.1 SD=6.3 0.25 
 Median=0.25 Median=0.25 Median=0.75  
Age category  
Child (1-18 years] 




































































Follow-up time (years) Mean=4.5 SD=2.3 Mean=4.5 SD=2.3 Mean=5.1 SD=2.4 0.31 
* χ2 test or t-test of difference between incidence cancers and cancer-free subjects 







Table 4.4 Genetic syndromes & other chromosomal abnormalities in CHOP cohort 
(n=625) 
 
Description n (%) 
22q11 deletion/DiGeorge syndrome 81 (12.96) 
Alagile syndrome  5 (0.80) 
Asplenia 38 (6.08) 
CHARGE 4 (0.64) 
Cleft lip/palate 1 (0.16) 
Cystic fibrosis 1 (0.16) 
Ellis van Creveld syndrome 2 (0.32) 
Freeman Sheldon syndrome 1 (0.16) 
Hirschprungs disease 2 (0.32) 
Horner syndrome 2 (0.32) 
Jacobson (11q deletion) syndrome 1 (0.16) 
Joubert syndrome 1 (0.16) 
Kawasaki disease 3 (0.48) 
Klinefelter syndrome 1 (0.16) 
Leopard syndrome 1 (0.16) 
Loeys-Dietz syndrome 2 (0.32) 
LQT syndrome 25 (4.00) 
Marfan syndrome 6 (0.96) 
Muscular dystrophy/myopathy 1 (0.16) 
Neurofibromatosis 2 (0.32) 
Noonan syndrome 10 (1.60) 
Peters syndrome 1 (0.16) 
Rubinstein-Taybi syndrome 1 (0.16) 
Scimitar syndrome 9 (1.44) 
Trisomy 18 4 (0.64) 
Trisomy 21 281 (44.96) 
Turner syndrome (45XO) 20 (3.20) 
William syndrome 7 (1.12) 
Wolff-Parkinson-White syndrome 5 (0.80) 
X-linked chronic granulomatous disease 1 (0.16) 
Dysmorphic features, no identified syndrome 91 (14.56) 
Other chromosomal abnormality 15 (2.40) 
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* See appendix for definitions 
† DFNS: dysmorphic features, no syndrome 
 
 
Sex CHD diagnosis* Cancer diagnosis Cancer type Genetic syndrome 
Male HLHS Cranial teratoma Brain/CNS DFNS† 
Female CoA Glioma  Brain/CNS  
Male TOF Neuroblastoma  Brain/CNS  
Female CoA Neuroblastoma  Brain/CNS  
Female HLHS Neuroblastoma  Brain/CNS Turner syndrome 
Female TOF Primitive neuroectodermal tumor  Brain/CNS  
Female PDA Hodgkin lymphoma Hematological  
Female PHTN Lymphoma  Hematological  
Female AVSD Lymphoproliferative Disease/Disorder Hematological Trisomy 21 
Female DCM Lymphoproliferative Disease/Disorder Hematological  
Male VSD Myelodysplastic syndrome  Hematological Monsomy 7 
Male VSD Myeloproliferative disease  Hematological Trisomy 21 
Male AVSD Myeloproliferative disease  Hematological Trisomy 21 
Male AVSD Myeloproliferative disease  Hematological Trisomy 21 
Male DILV Precursor B-cell lymphoblastic leukemia Hematological  
Female ASD Precursor B-cell lymphoblastic leukemia  Hematological Trisomy 21 
Female VSD Precursor B-cell lymphoblastic leukemia  Hematological Trisomy 21 
Male AVSD Precursor B-cell lymphoblastic leukemia  Hematological Trisomy 21 
Male Heart failure Precursor T-cell lymphoblastic lymphoma Hematological  
Male Ao aneurysm Paraganglioma  Neuroendocrine  
Female ASD Hepatoblastoma Other solid   
Female PDA Teratoma  Other solid   
Male DCM Embryonal rhabdomyosarcoma Soft tissue  
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Table 4.6 Pediatric cancer rates in the CHOP cohort (n=4,523) 
 n Cancer 
incidence rate 
(per year) 
Hazard ratio (95% 
CI) 
P value 
Overall cohort cancer rate 23 0.00070   
Male 11 0.00052 1.00  
Female 12 0.00085 1.35 (0.60 – 3.06) 0.47 
No genetic syndrome 13 0.00049 1.00  
Any genetic syndrome 10 0.0025 5.09 (2.20 – 11.77) 0.0001 
≤ 1.0 mSv Radiation*  6 0.00039 1.00  
>1.0 mSv Radiation*  8 0.00056 1.39 (0.48 – 4.102) 0.54 
Cumulative radiation  
(per mSv)*   0.999 (0.985 – 1.014) 0.94 











SIR 95% CI P value 
Overall cohort SIR 23 6.18 3.72 1.53 – 9.04 0.0037 
Female 12 2.57 4.67 1.21 – 18.00 0.025 
Male 11 3.62 3.04 0.93 – 9.97 0.067 
Any genetic syndrome 10 0.80 12.49 1.28 – 121.74 0.030 
No genetic syndrome 13 5.39 2.41 0.88 – 6.60 0.086 
>1.0 mSv Radiation*  8 2.78 2.88 0.74 – 11.27 0.13 
≤ 1.0 mSv Radiation*  6 3.02 1.99 0.50 – 7.94 0.33 






Figure 4.1 Incident cancers (n=23) by genetic syndromes Cancers identified in the 
CHOP CHD cohort are displayed, categorized by tumor site and histology as defined in 






Figure 4.2 Cumulative diagnostic radiation exposure (mSv) by cancer status  
Effective radiation exposure from diagnostic exams is shown on a log-scale for 4,162 
CHD patients with available data.  a) The distribution of radiation among children that 
developed cancer during follow-up with available data is shown (n=14). Mean = 13.5 
mSv, Standard deviation (SD) = 29.3 mSv, Median = 2.9 mSv.  b) The distribution of 
radiation among children that remained cancer-free during follow-up with available data 











 In this dissertation, I have shown that epidemiologic methods provide a way to 
understand the underlying architecture of complex diseases.  We have gained significant 
understanding of the epidemiology of colorectal cancer, congenital heart disease, and 
childhood cancer by combining our current understanding of the biology of these diseases 
with advances in technology, genetic epidemiology, and classic epidemiologic methods.  
Not only have we gained insight into these diseases individually, but we have also 
identified a previously unrecognized link between congenital heart disease and cancer, 
suggesting that future studies can take advantage of this relationship to further understand 
the common link between the epidemiology of these two diseases. 
We investigated the genetic and functional basis of associations at two candidate 
SNPs identified from the MECC GWAS, rs10210149 on chromosome 2q11.2-q12 and 
rs16931815 on chromosome 12p11.23.  Specifically, MECC subjects were screened for 
pathogenic mutations and allele-specific expression analyses were performed for GPR45, 
STK38L, and TGFBRAP1.  Of these three genes, GPR45 was associated with a 27% 
increase in expression of one allele for each additional copy of the C allele of rs10210149 
(p-trend = 0.01). Consistent with the conclusions drawn from other GWAS studies and 
subsequent functional analyses, we suggest that the underlying causal variant at 
rs10210149 affects gene expression. Elucidating the functional consequences of these 
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GWAS variants has been challenging, but provides an opportunity for 
understanding the mechanisms of colorectal cancer. 
We next investigated variation in ISL1 and risk of CHD in a two-stage case-
control study, identifying ISL1 as a candidate susceptibility gene for human CHD by its 
integral role in the regulation of the secondary heart field. Eight genic and flanking ISL1 
SNPs were significantly associated with CHD. Our results demonstrate that two different 
ISL1 haplotypes contribute to risk of CHD in white (Summary Odds Ratio (OR) =1.27, 
95% Confidence Interval (CI) 1.09 – 1.48, P = 0.0018) and black/African American 
populations (Summary OR=1.57, 95% CI 1.07 – 2.30, P = 0.0216), suggesting a new role 
for known regulatory genes of cardiomyocytes in human disease. These data provide 
strong evidence that congenital heart disease is consistent with the common disease – 
common variant hypothesis in two different ethnic groups. Further, we provide new 
insight into the variety of congenital heart disease phenotypes that can be produced from 
genetic abnormalities in a single source population of cardiac progenitor cells. 
 Our efforts to understand the epidemiology of both colorectal cancer and 
congenital heart disease are linked by a well known association between selected forms 
of congenital heart disease and cancer. In the CHOP cohort study, we showed that 
children with CHD demonstrated a 3.7-fold increase in the rate of pediatric cancer 
compared to the US population (Standardized Incidence Ratio (SIR) = 3.72, 95% CI = 
1.53 – 9.04, p = 0.0037). Rates were higher for children with both syndromic 
(SIR=12.49, 95% CI 1.28 – 121.74, p=0.03) and non-syndromic (SIR=2.41, 95% CI 0.88 
– 6.60, p=0.086) heart disease. We propose that further studies of cancer incidence 
among children with CHD may provide a way to unravel the complex biology underlying 
116
 
this relationship, providing significant insight into the causes of both CHD and pediatric 
cancers.  
 In this dissertation, I applied epidemiologic methods to further understand the 
etiology of three complex diseases: colorectal cancer, childhood cancers, and congenital 
heart disease (CHD).  The characterization of allele-specific expression of GPR45, 
STK38L, and TGFBRAP1 in the MECC study demonstrated the value of studies that 
combine genetic epidemiology and functional data when evaluating candidate genes 
identified from genome-wide association studies.  Our study of genetic variation in ISL1 
and risk of human congenital heart disease demonstrated a previously unidentified role 
for common variation in two different ethnic populations.  Future studies should 
investigate the association between risk of CHD and common variation in other genes 
that are critical to cardiomyocyte regulation and differentiation, which may also be 
involved in susceptibility to this disease. Finally, evaluating the association between 
childhood cancers and CHD has demonstrated a link between the biology and 
epidemiology of both diseases. Understanding the environmental exposures and genetic 
abnormalities that are found among the CHD patients that developed cancer may provide 






CHD Diagnosis Definition 
AA Atrial abnormality, other 
AI Aortic insufficiency 
AP window Aortopulmonary window 
ASD Atrial septal defect 
ASD, Prim ASD, primum 
ASD, Sec ASD, secundum 
ASD, SV ASD, Sinus venosus 
AVSD  Atrioventricular septal defect 
AVSD, Comp Atrioventricular septal defect, complete 
AVSD, Inc Atrioventricular septal defect, incomplete 
Ao aneurysm Aortic aneurysm 
Ao dissection Aortic dissection 
Ao stenosis  Aortic stenosis  
Bilateral SVC Bilateral superior vena cava 
CCAVC, unbalanced Complete common atroventricular canal 
CDH  Congenital diagphragmatic hernia 
CoA Coarctation of the aorta 
D-TGA D-transposition of the great arteries 
DCM Dilated cardiomyopathy 
DCRV Double chambered right ventricle 
DILV Double inlet left ventricle 
DIRV Double inlet right ventricle 
DOLV Double outlet left ventricle 
DORV  Double outlet right ventricle 
HCM Hypertrophic cardiomyopathy 
HLHS Hypoplastic left heart syndrome 
IAA Interrupted aortic arch 
L-TGA Congenitally corrected transpostion of the great arteries 
MR  Mitral regurgitation 
MS Mitral stenosis 
MV abnormality Mitral valve abnormality 
MV atresia Mitral valve atresia 
PA Pulmonary atresia 
PA stenosis Pulmonary artery stenosis 
PA/VSD Pulmonary atresia/ventricular septal defect 
PAPVC Partial anomalous pulmonary venous connection 
PDA  Patent ductus arteriosus 
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CHD Diagnosis Definition 
PHTN Pulmonary hypertension 
PI Pulmonary insufficiency 
PS  Pulmonary stenosis 
PV stenosis Pulmonary vein stenosis 
PVD Pulmonary vascular disease 
Pericardial disease, NOS Pericardial disease, not otherwise specified 
RVOTO Right ventricular outflow tract obstruction 
TAPVC Total anomalous pulmonary venous connection 
TOF Tetralogy of Fallot 
TOF/APV Tetralogy of Fallot, absent pulmonary valve 
VSD  Ventricular septal defect 
VSD, CS Ventricular septal defect, conoseptal 
VSD, CV Ventricular septal defect, conoventricular 
VSD, I Ventricular septal defect, inlet 





Agha MM, Williams JI, Marrett L, To T, Zipursky A, Dodds L (2005). Congenital 
abnormalities and childhood cancer. Cancer 103: 1939-48. 
 
Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H (1997). Independent requirement 
for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature 385: 257-60. 
 
Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z et al (2009). 
Neurofibromatosis type 2. Lancet 373: 1974-86. 
 
Bat L, Pines A, Ron E, Rosenblum Y, Niv Y, Shemesh E (1986). Colorectal adenomatous 
polyps and carcinoma in Ashkenazi and non-Ashkenazi Jews in Israel. Cancer 58: 1167-
71. 
 
Bjorge T, Cnattingius S, Lie RT, Tretli S, Engeland A (2008). Cancer risk in children 
with birth defects and in their families: a population based cohort study of 5.2 million 
children from Norway and Sweden. Cancer Epidemiol Biomarkers Prev 17: 500-6. 
 
Black BL (2007). Transcriptional pathways in second heart field development. Semin 
Cell Dev Biol 18: 67-76. 
 
Bos JL (1989). ras oncogenes in human cancer: a review. Cancer Res 49: 4682-9. 
 
Brenner H, Chang-Claude J, Seiler CM, Sturmer T, Hoffmeister M (2006). Does a 
negative screening colonoscopy ever need to be repeated? Gut 55: 1145-50. 
 
Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A et al 
(2007). A genome-wide association study shows that common alleles of SMAD7 
influence colorectal cancer risk. Nat Genet 39: 1315-7. 
 
Brunak S, Engelbrecht J, Knudsen S (1991). Prediction of human mRNA donor and 
acceptor sites from the DNA sequence. J Mol Biol 220: 49-65. 
 
Bu L, Jiang X, Martin-Puig S, Caron L, Zhu S, Shao Y et al (2009). Human ISL1 heart 
progenitors generate diverse multipotent cardiovascular cell lineages. Nature 460: 113-7. 
 
Buckingham M, Meilhac S, Zaffran S (2005). Building the mammalian heart from two 




Cai CL, Liang X, Shi Y, Chu PH, Pfaff SL, Chen J et al (2003). Isl1 identifies a cardiac 
progenitor population that proliferates prior to differentiation and contributes a majority 
of cells to the heart. Dev Cell 5: 877-89. 
 
Carstensen B, Soll-Johanning H, Villadsen E, Sondergaard JO, Lynge E (1996). Familial 
aggregation of colorectal cancer in the general population. Int J Cancer 68: 428-35. 
 
Castellsague E, Gonzalez S, Guino E, Stevens KN, Borras E, Raymond VM et al (2010). 
Allele-Specific Expression of APC in Adenomatous Polyposis Families. 
Gastroenterology. 
 
Connor JA, Arons RR, Figueroa M, Gebbie KM (2004). Clinical outcomes and secondary 
diagnoses for infants born with hypoplastic left heart syndrome. Pediatrics 114: e160-5. 
 
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002). Mutations of 
the BRAF gene in human cancer. Nature 417: 949-54. 
 
de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, de Vries EG, Sijmons RH et 
al (2002). Low-penetrance genes and their involvement in colorectal cancer 
susceptibility. Cancer Epidemiol Biomarkers Prev 11: 1332-52. 
 
Denayer E, de Ravel T, Legius E (2008). Clinical and molecular aspects of RAS related 
disorders. J Med Genet 45: 695-703. 
 
Ferlay J, Parkin DM, Steliarova-Foucher E (2010). Estimates of cancer incidence and 
mortality in Europe in 2008. Eur J Cancer 46: 765-81. 
 
Fireman Z, Sandler E, Kopelman Y, Segal A, Sternberg A (2001). Ethnic differences in 
colorectal cancer among Arab and Jewish neighbors in Israel. Am J Gastroenterol 96: 
204-7. 
 
Freeman SB, Taft LF, Dooley KJ, Allran K, Sherman SL, Hassold TJ et al (1998). 
Population-based study of congenital heart defects in Down syndrome. Am J Med Genet 
80: 213-7. 
 
Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA et al (2003). 
GATA4 mutations cause human congenital heart defects and reveal an interaction with 
TBX5. Nature 424: 443-7. 
 
Goss KH, Groden J (2000). Biology of the adenomatous polyposis coli tumor suppressor. 
J Clin Oncol 18: 1967-79. 
 
Gripp KW (2005). Tumor predisposition in Costello syndrome. Am J Med Genet C Semin 




Gross TG, Savoldo B, Punnett A (2010). Posttransplant lymphoproliferative diseases. 
Pediatr Clin North Am 57: 481-503, table of contents. 
 
Gruber PJ, Epstein JA (2004). Development gone awry: congenital heart disease. Circ 
Res 94: 273-83. 
 
Gruber SB, Moreno V, Rozek LS, Rennerts HS, Lejbkowicz F, Bonner JD et al (2007). 
Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biol Ther 6: 
1143-7. 
 
Hammer GP, Seidenbusch MC, Schneider K, Regulla DF, Zeeb H, Spix C et al (2009). A 
cohort study of childhood cancer incidence after postnatal diagnostic X-ray exposure. 
Radiat Res 171: 504-12. 
 
Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P, Brunak S (1996). 
Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global 
sequence information. Nucleic Acids Res 24: 3439-52. 
 
Hergovich A, Stegert MR, Schmitz D, Hemmings BA (2006). NDR kinases regulate 
essential cell processes from yeast to humans. Nat Rev Mol Cell Biol 7: 253-64. 
 
Hickey EJ, Veldtman G, Bradley TJ, Gengsakul A, Manlhiot C, Williams WG et al 
(2009). Late risk of outcomes for adults with repaired tetralogy of Fallot from an 
inception cohort spanning four decades. Eur J Cardiothorac Surg 35: 156-64; discussion 
164. 
 
Hoffman JI, Kaplan S (2002). The incidence of congenital heart disease. J Am Coll 
Cardiol 39: 1890-900. 
 
Hoffman JI, Kaplan S, Liberthson RR (2004). Prevalence of congenital heart disease. Am 
Heart J 147: 425-39. 
 
Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S et al (2008). 
Meta-analysis of genome-wide association data identifies four new susceptibility loci for 
colorectal cancer. Nat Genet 40: 1426-35. 
 
Huls G, Koornstra JJ, Kleibeuker JH (2003). Non-steroidal anti-inflammatory drugs and 
molecular carcinogenesis of colorectal carcinomas. Lancet 362: 230-2. 
 
Jaeger E, Webb E, Howarth K, Carvajal-Carmona L, Rowan A, Broderick P et al (2008). 
Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 
influence colorectal cancer risk. Nat Genet 40: 26-8. 
 
Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR et al (2007). 
Noninherited risk factors and congenital cardiovascular defects: current knowledge: a 
scientific statement from the American Heart Association Council on Cardiovascular 
122
 
Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 
115: 2995-3014. 
 
Kemp Z, Thirlwell C, Sieber O, Silver A, Tomlinson I (2004). An update on the genetics 
of colorectal cancer. Hum Mol Genet 13 Spec No 2: R177-85. 
 
Knight JC (2005). Regulatory polymorphisms underlying complex disease traits. J Mol 
Med 83: 97-109. 
 
Kusakai G, Suzuki A, Ogura T, Miyamoto S, Ochiai A, Kaminishi M et al (2004). ARK5 
expression in colorectal cancer and its implications for tumor progression. Am J Pathol 
164: 987-95. 
 
Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM et al (1997). 
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 
17: 79-83. 
 
Larsson SC, Wolk A (2006). Meat consumption and risk of colorectal cancer: a meta-
analysis of prospective studies. Int J Cancer 119: 2657-64. 
 
Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodard S et al (2005). Postnatal 
isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433: 647-53. 
 
Li Y AG (2006). Mach 1.0: Rapid Haplotype Reconstruction and Missing Genotype 
Inference. Am J Hum Genet. 
 
Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW et al 
(2010). Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J 
Natl Cancer Inst 102: 1012-22. 
 
Lo HS, Wang Z, Hu Y, Yang HH, Gere S, Buetow KH et al (2003). Allelic variation in 
gene expression is common in the human genome. Genome Res 13: 1855-62. 
 
Lynch HT, Weisenburger DD, Quinn-Laquer B, Watson P, Lynch JF, Sanger WG (2002). 
Hereditary chronic lymphocytic leukemia: an extended family study and literature 
review. Am J Med Genet 115: 113-7. 
 
Marchese A, Sawzdargo M, Nguyen T, Cheng R, Heng HH, Nowak T et al (1999). 
Discovery of three novel orphan G-protein-coupled receptors. Genomics 56: 12-21. 
 
Marra G, Boland CR (1995). Hereditary nonpolyposis colorectal cancer: the syndrome, 
the genes, and historical perspectives. J Natl Cancer Inst 87: 1114-25. 
 
Modan B, Keinan L, Blumstein T, Sadetzki S (2000). Cancer following cardiac 




Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I et al (2006). 
Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of 
colorectal cancer. Clin Cancer Res 12: 2101-8. 
 
Moretti A, Caron L, Nakano A, Lam JT, Bernshausen A, Chen Y et al (2006). 
Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and 
endothelial cell diversification. Cell 127: 1151-65. 
 
Narod SA, Hawkins MM, Robertson CM, Stiller CA (1997). Congenital anomalies and 
childhood cancer in Great Britain. Am J Hum Genet 60: 474-85. 
 
Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR et al 
(2004). Methods for high-density admixture mapping of disease genes. Am J Hum Genet 
74: 979-1000. 
 
Pertea M, Lin X, Salzberg SL (2001). GeneSplicer: a new computational method for 
splice site prediction. Nucleic Acids Res 29: 1185-90. 
 
Piard F, Martin L, Chapusot C, Ponnelle T, Faivre J (2002). [Genetic pathways in 
colorectal cancer: interest for the pathologist]. Ann Pathol 22: 277-88. 
 
Pierpont ME, Basson CT, Benson DW, Jr., Gelb BD, Giglia TM, Goldmuntz E et al 
(2007). Genetic basis for congenital heart defects: current knowledge: a scientific 
statement from the American Heart Association Congenital Cardiac Defects Committee, 
Council on Cardiovascular Disease in the Young: endorsed by the American Academy of 
Pediatrics. Circulation 115: 3015-38. 
 
Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H et al (2009). 
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in 
colorectal cancer. Nat Genet 41: 882-4. 
 
Posch MG, Perrot A, Schmitt K, Mittelhaus S, Esenwein EM, Stiller B et al (2008). 
Mutations in GATA4, NKX2.5, CRELD1, and BMP4 are infrequently found in patients 
with congenital cardiac septal defects. Am J Med Genet A 146A: 251-3. 
 
Rankin J, Silf KA, Pearce MS, Parker L, Ward Platt M (2008). Congenital anomaly and 
childhood cancer: A population-based, record linkage study. Pediatr Blood Cancer 51: 
608-12. 
 
Reich DE, Lander ES (2001). On the allelic spectrum of human disease. Trends Genet 
17: 502-10. 
 




Rose V, Gold RJ, Lindsay G, Allen M (1985). A possible increase in the incidence of 
congenital heart defects among the offspring of affected parents. J Am Coll Cardiol 6: 
376-82. 
 
Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I (2005). Long-term 
follow-up for brain tumor development after childhood exposure to ionizing radiation for 
tinea capitis. Radiat Res 163: 424-32. 
 
Scheet P, Stephens M (2006). A fast and flexible statistical model for large-scale 
population genotype data: applications to inferring missing genotypes and haplotypic 
phase. Am J Hum Genet 78: 629-44. 
 
Schnater JM, Kohler SE, Lamers WH, von Schweinitz D, Aronson DC (2003). Where do 
we stand with hepatoblastoma? A review. Cancer 98: 668-78. 
 
Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA (2008). Cancer 
incidence in women with Turner syndrome in Great Britain: a national cohort study. 
Lancet Oncol 9: 239-46. 
 
Schott JJ, Benson DW, Basson CT, Pease W, Silberbach GM, Moak JP et al (1998). 
Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science 
281: 108-11. 
 
Schrader KA, Nelson TN, De Luca A, Huntsman DG, McGillivray BC (2009). Multiple 
granular cell tumors are an associated feature of LEOPARD syndrome caused by 
mutation in PTPN11. Clin Genet 75: 185-9. 
 
Schultz AH, Wernovsky G (2005). Late outcomes in patients with surgically treated 
congenital heart disease. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu: 145-
56. 
 
Sijmons RH, Hofstra RM, Wijburg FA, Links TP, Zwierstra RP, Vermey A et al (1998). 
Oncological implications of RET gene mutations in Hirschsprung's disease. Gut 43: 542-
7. 
 
Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A 
et al (2004). A high-density admixture map for disease gene discovery in african 
americans. Am J Hum Genet 74: 1001-13. 
 
Sorensen SA, Mulvihill JJ, Nielsen A (1986). Long-term follow-up of von 
Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 
314: 1010-5. 
 
Sotelo J, Esposito D, Duhagon MA, Banfield K, Mehalko J, Liao H et al (2010). Long-




Stiller CA (2004). Epidemiology and genetics of childhood cancer. Oncogene 23: 6429-
44. 
 
Sun Y, Liang X, Najafi N, Cass M, Lin L, Cai CL et al (2007). Islet 1 is expressed in 
distinct cardiovascular lineages, including pacemaker and coronary vascular cells. Dev 
Biol 304: 286-96. 
 
Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Esumi H (2003). ARK5 suppresses 
the cell death induced by nutrient starvation and death receptors via inhibition of caspase 
8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 22: 6177-
82. 
 
Suzuki A, Ogura T, Esumi H (2006). NDR2 acts as the upstream kinase of ARK5 during 
insulin-like growth factor-1 signaling. J Biol Chem 281: 13915-21. 
 
Suzuki M, Igarashi R, Sekiya M, Utsugi T, Morishita S, Yukawa M et al (2004). 
Dynactin is involved in a checkpoint to monitor cell wall synthesis in Saccharomyces 
cerevisiae. Nat Cell Biol 6: 861-71. 
 
Tartaglia M, Gelb BD (2005). Germ-line and somatic PTPN11 mutations in human 
disease. Eur J Med Genet 48: 81-96. 
 
Tenesa A, Dunlop MG (2009). New insights into the aetiology of colorectal cancer from 
genome-wide association studies. Nat Rev Genet 10: 353-8. 
 
Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N et al (2008). 
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 
11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 40: 631-7. 
 
Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD et al 
(2009). GPR109A is a G-protein-coupled receptor for the bacterial fermentation product 
butyrate and functions as a tumor suppressor in colon. Cancer Res 69: 2826-32. 
 
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S et al (2007). 
A genome-wide association scan of tag SNPs identifies a susceptibility variant for 
colorectal cancer at 8q24.21. Nat Genet 39: 984-8. 
 
Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM et al 
(2008). A genome-wide association study identifies colorectal cancer susceptibility loci 
on chromosomes 10p14 and 8q23.3. Nat Genet 40: 623-30. 
 
Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T et al (2009). 
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 




Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT et al (2003). The 
G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A 
100: 4903-8. 
 
Verheugt CL, Uiterwaal CS, Grobbee DE, Mulder BJ (2008). Long-term prognosis of 
congenital heart defects: a systematic review. Int J Cardiol 131: 25-32. 
 
Wang WY, Barratt BJ, Clayton DG, Todd JA (2005). Genome-wide association studies: 
theoretical and practical concerns. Nat Rev Genet 6: 109-18. 
 
Whittemore R, Hobbins JC, Engle MA (1982). Pregnancy and its outcome in women 
with and without surgical treatment of congenital heart disease. Am J Cardiol 50: 641-51. 
 
Whittemore R, Wells JA, Castellsague X (1994). A second-generation study of 427 
probands with congenital heart defects and their 837 children. J Am Coll Cardiol 23: 
1459-67. 
 
WHO (2003). World Cancer Report (eds Stewart B. W. & Kleihues P.).  13. 
 
Wolin KY, Yan Y, Colditz GA, Lee IM (2009). Physical activity and colon cancer 
prevention: a meta-analysis. Br J Cancer 100: 611-6. 
 
Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al (2007). The genomic 
landscapes of human breast and colorectal cancers. Science 318: 1108-13. 
 
Wu SM, Chien KR, Mummery C (2008). Origins and fates of cardiovascular progenitor 
cells. Cell 132: 537-43. 
 
Wurthner JU, Frank DB, Felici A, Green HM, Cao Z, Schneider MD et al (2001). 
Transforming growth factor-beta receptor-associated protein 1 is a Smad4 chaperone. J 
Biol Chem 276: 19495-502. 
 
Yan H, Dobbie Z, Gruber SB, Markowitz S, Romans K, Giardiello FM et al (2002). 
Small changes in expression affect predisposition to tumorigenesis. Nat Genet 30: 25-6. 
 
Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM et al (2007). 
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 
chromosome 8q24. Nat Genet 39: 989-94. 
 
 
 
